<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cold agglutinin disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cold agglutinin disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cold agglutinin disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sigbjørn Berentsen, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlo Brugnara, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Brodsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cold agglutinin disease (CAD) is a form of autoimmune hemolytic anemia (AIHA) in which cold agglutinins (IgM autoantibodies against red blood cell [RBC] antigens that bind at cold temperatures) can cause clinical symptoms related to RBC agglutination in cooler parts of the body and hemolytic anemia.</p><p>This topic reviews the pathophysiology, evaluation, and treatment of CAD.</p><p>Warm AIHA and other cold-related hematologic disorders are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warm AIHA</strong> (immune hemolysis at normal body temperature) – (See  <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxysmal cold hemoglobinuria</strong> (intravascular hemolysis due to a cold-sensitive antibody) – (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryoglobulinemia</strong> (immunoglobulins that precipitate in the cold; not associated with hemolysis) – (See  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryofibrinogenemia</strong> – (See  <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">"Disorders of fibrinogen", section on 'Cryofibrinogenemia'</a>.)</p><p></p><p class="headingAnchor" id="H1445188192"><span class="h1">TERMINOLOGY AND DISTINCTION AMONG SYNDROMES</span><span class="headingEndMark"> — </span>There are three major types of cold-sensitive antibodies that can cause clinical manifestations: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold agglutinins/CAD</strong> – Cold agglutinins can cause CAD. These are antibodies that recognize antigens on red blood cells (RBCs) at temperatures below normal core body temperature. They can cause agglutination of the RBCs  (<a class="graphic graphic_picture graphicRef50522" href="/z/d/graphic/50522.html" rel="external">picture 1</a>) and extravascular hemolysis, resulting in anemia, typically without hemoglobinuria.</p><p></p><p class="bulletIndent1">Cold agglutinins may be seen with the primary cold agglutinin disease (CAD) or secondary cold agglutinin syndrome (CAS) [<a href="#rid1">1-3</a>]. The antibodies are typically immunoglobulin M (IgM) and the antigen is typically "I" or "i" on the RBC surface.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary CAD</strong> – Primary CAD (also called idiopathic CAD) is used to refer to cold agglutinins that cause RBC agglutination and extravascular hemolysis in the absence of an underlying disorder. As discussed below, these individuals are thought to have a low-grade clonal lymphoproliferative bone marrow disorder [<a href="#rid4">4</a>]. (See <a class="local">'Cold agglutinins'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary CAS</strong> – When cold agglutinins arise in the setting of an underlying clinical disease such as a specific infection, autoimmune disorder, or overt lymphoma, the syndrome is referred to as secondary CAS. (See <a class="local">'Associated disorders'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donath-Landsteiner antibodies/PCH</strong> – Donath-Landsteiner antibodies cause paroxysmal cold hemoglobinuria (PCH). These are antibodies that recognize RBC antigens at cold temperatures, but unlike cold agglutinins, these antibodies fix complement and cause hemolysis in the circulation (intravascular hemolysis). This is why patients have symptoms associated with hemoglobinemia and hemoglobinuria (eg, flank pain, dark urine). The antibodies are usually IgG and they are often directed against the "P" antigen on RBCs. (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryoglobulins/vasculitis</strong> – Cryoglobulins can cause a vasculitic picture. These are antibodies that form immune complexes in the cold; they generally do not interact with RBCs. Cryoglobulins can cause a systemic vasculitis, a systemic inflammatory syndrome, or vascular occlusion. (See  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>.)</p><p></p><p>The clinical features associated with the above disorders are summarized in the table  (<a class="graphic graphic_table graphicRef103370" href="/z/d/graphic/103370.html" rel="external">table 1</a>).</p><p>The antibodies may share some clinical features, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Development after infections or in the setting of lymphoproliferative or autoimmune disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Association with Raynaud phenomenon</p><p class="bulletIndent1"><span class="glyph">●</span>Association with inflammatory or neoplastic disorders that cause anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Some antibodies may act as both cold agglutinins and cryoglobulins (this is rare)</p><p></p><p class="headingAnchor" id="H377443360"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H1566834047"><span class="h2">RBC antigens</span><span class="headingEndMark"> — </span>There are a variety of antigenic epitopes on the surface of red blood cells (RBCs), many of which have been serologically defined as blood group antigens. Cold agglutinins react with RBC antigens that contain polysaccharide epitopes on glycoproteins or glycolipids such as ceramide or glycophorins.</p><p>Most cold agglutinins are directed against "I" or "i" antigens of the I blood group (referred to as "big I" or "little i" respectively). (See  <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">"Red blood cell antigens and antibodies", section on 'Lewis, P1P(K), GLOB, and I blood group systems'</a>.)</p><p>The big I and little i antigens are ubiquitous (present on all cell membranes) and structurally related [<a href="#rid5">5-7</a>]. Little i is the predominant structure on fetal RBCs. It consists of a straight-chain polymer of at least two lactosamines. After birth, an enzyme becomes activated that can add additional lactosamine disaccharides to galactose, resulting in a branched chain structure that constitutes the big I antigen. Thus, little i is progressively converted to big I during infancy, and most children become big I positive by the age of two years. The function of the big I and little i antigens is unknown.</p><p class="bulletIndent1"><span class="glyph">●</span>Big I is present on RBCs in approximately 99 percent of people</p><p class="bulletIndent1"><span class="glyph">●</span>Little i is present on RBCs in &lt;1 percent of the population; these individuals are also called "big I negative"</p><p></p><p>In certain settings, the antigen may be associated with a specific infectious cause of cold agglutinin production (usually the I antigen in <em>Mycoplasma pneumoniae</em> infection and the i antigen in infectious mononucleosis)  (<a class="graphic graphic_table graphicRef61974" href="/z/d/graphic/61974.html" rel="external">table 2</a>). However, the antigenic target of the cold agglutinin cannot be used to distinguish among any underlying conditions.</p><p>These complex polysaccharides also serve as precursors for assembly of the ABO and Lewis blood group antigens. Sometimes, the epitope of particular anti-I or anti-i antibodies may include parts of the ABO or Lewis antigens. The specificity of these antibodies is designated anti-IA, anti-IB, etc. Rare antibodies react equally well with the I and the i structure; these antibodies are designated "anti-j" [<a href="#rid8">8</a>].</p><p>Less commonly, antibodies have been described that react with RBCs that have been treated with proteases (referred to as "anti-Pr") or with sialidase. Those that are dependent upon sialic acid (which may be added to the end of the complex polysaccharide structures) are designated "Sia" followed by an "l" if on the linear (i-like structure), "b" if on the branched (I-like structure), or both if on both structures. As an example, Sia-l would designate a sialic acid-dependent structure on the linear polysaccharide. Sialic acid-dependent antibodies are rare.</p><p class="headingAnchor" id="H3360841552"><span class="h2">Cold agglutinins</span><span class="headingEndMark"> — </span>Cold agglutinins are autoantibodies directed against RBC antigens. They have the following properties:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isotype</strong> – Most cold agglutinins are IgM [<a href="#rid9">9</a>]. IgA or IgG cold agglutinins have occasionally been reported, although IgA cold agglutinins probably do not result in CAD [<a href="#rid10">10-14</a>]. IgM antibodies are pentameric, which places antigen-binding sites sufficiently far apart to allow them to bridge the distance between RBCs. This binding of multiple RBCs by the same IgM molecule is the basis for RBC agglutination. Even a small amount of antibodies, perhaps as few as 25 per RBC, can produce obvious agglutination [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Light chain</strong> – In CAD, cold agglutinins are more likely to have kappa than lambda light chains. In a large cohort of patients with CAD from Norway, 94 percent of cold agglutinins had kappa light chains [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specificity</strong> – In general, the vast majority of cold agglutinins are either anti-I or anti-i; the table summarizes their properties  (<a class="graphic graphic_table graphicRef61974" href="/z/d/graphic/61974.html" rel="external">table 2</a>). In CAD, they are nearly always anti-I. (See <a class="local">'RBC antigens'</a> above.) </p><p></p><p class="bulletIndent1">Specificity can be determined using serologic methods, although this is not required for routine management other than transfusion. Previously, the specificity was inferred based on whether the antibodies were more effective at agglutinating RBCs from adults or from umbilical cord blood [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Titer</strong> – The titer is the number of dilutions after which the antibody can still cause agglutination; it reflects antibody concentration and avidity. Generally, a titer ≥64 is considered clinically significant. (See <a class="local">'Antibody titer and thermal amplitude'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thermal amplitude</strong> – The temperature range at which the antibodies are active is referred to as the thermal range or thermal amplitude. The typical optimum temperature for antigen binding to cold agglutinins is 3 to 4°C (refrigerator temperature), but pathogenic cold agglutinins often have a thermal amplitude of 28 to 30°C or more and will be active at temperatures that occur in acral areas of the body [<a href="#rid9">9</a>]. Antibodies with a lower thermal amplitude will cause agglutination in vitro but are unlikely to cause clinical disease. (See <a class="local">'Antibody titer and thermal amplitude'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonality</strong> – Cold agglutinins can be monoclonal (derived from a single clone of lymphocytes; having a single, uniform epitope specificity) or polyclonal (derived from multiple independent lymphocytes; having multiple epitope specificities). Monoclonal cold agglutinins are typically associated with lymphoproliferative disorders, and they are more pathogenic than polyclonal cold agglutinins [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Most cases of primary CAD are thought to originate from a low-grade lymphoproliferative disorder and thus to be monoclonal. (See <a class="local">'Primary CAD-associated lymphoproliferative disorder'</a> below.)</p><p></p><p class="bulletIndent1">Most cases of secondary cold agglutinin syndrome (CAS) associated with a lymphoid malignancy are monoclonal, and most cases of secondary CAS associated with a viral infection are polyclonal [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1">For therapy, monoclonal cold agglutinins generally require systemic agents to eradicate the B-cell clone that is producing them (see <a class="local">'Therapies directed at the pathogenic process'</a> below); polyclonal cold agglutinins associated with infections resolve spontaneously in most cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structure</strong> – Molecular characterization of cold agglutinins has demonstrated other features of their structure. As an example, most cold agglutinin heavy chains appear derived from a restricted set of variable domains. Out of approximately 100 possible V(H) genes available, nearly all antibodies of I, i, or j (I and i) specificity use a single V(H) gene (<em>IGHV4-34</em>; formerly called VH4-21) [<a href="#rid18">18-22</a>]. Monoclonal <em>IGHV4-34</em> gene rearrangement was also seen in eight of eight samples from a study discussed below [<a href="#rid23">23</a>] (see <a class="local">'Primary CAD-associated lymphoproliferative disorder'</a> below). This may make them easier to identify in the laboratory. </p><p></p><p class="bulletIndent1">T<em>he IGHV4-</em>34 variable region is also used by clinically important IgM antibodies against other antigens such as other blood group antigens, deoxyribonucleic acid (DNA; in systemic lupus erythematosus [SLE]), and endotoxin [<a href="#rid24">24-26</a>]. Additional studies using mutagenesis or crystallography have determined the specific amino acid residues responsible for binding to polysaccharide antigens [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Binding properties</strong> – Cold agglutinins bind weakly to RBCs at temperatures approaching body temperature and more strongly at lower temperatures. This is because the binding of cold agglutinins to the carbohydrate antigens such as "I" and "i" occurs predominantly through weak bonds such as hydrogen bonds and van der Waals forces rather than through ionic bonds. This weak reaction may be due to the nature of both the antigen and the antigen-binding site on the antibody, both of which are very restricted in their chemistry. </p><p></p><p class="bulletIndent1">These weak forces are made stronger by reduction in ambient temperature, which has the effect of reducing spontaneous Brownian movement; this feature of binding accounts for the cold-reactivity of cold agglutinins. This property of certain antibodies associated with hemolytic anemia that caused them to have a strong interaction with RBCs below core body temperature was the basis for the original description of these antibodies as cold agglutinins [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H2223161731"><span class="h2">Primary CAD-associated lymphoproliferative disorder</span><span class="headingEndMark"> — </span>Cold agglutinin-mediated autoimmune hemolytic anemia (AIHA) without an underlying disorder viral infection or lymphoid disorder is referred to as primary CAD. (See <a class="local">'Terminology and distinction among syndromes'</a> above.)</p><p>Despite the lack of an underlying malignancy, most cases of primary CAD produce a monoclonal cold agglutinin, suggesting a clonal proliferation of cells from a lymphoproliferative disorder. The term "CAD-associated lymphoproliferative disorder" has been proposed to describe this entity [<a href="#rid4">4,21</a>]. Previously, we referred to it as a "benign monoclonal variant" to distinguish it from overt lymphoma or other lymphoproliferative disorders. In 2022, CAD was recognized as a distinct lymphoid neoplasm in the World Health Organization (WHO) classification of hematolymphoid neoplasms [<a href="#rid30">30-32</a>].</p><p>The nature of this lymphoproliferative disorder was investigated in a study of 54 individuals with CAD who did not have evidence of an extramedullary lymphoma (none had lymphadenopathy, splenomegaly, or abnormal lymphocytes in the peripheral blood) in which a group of pathologists analyzed bone marrow samples using a standardized panel of flow cytometry, immunohistochemistry, and mutational analysis  (<a class="graphic graphic_picture graphicRef119671" href="/z/d/graphic/119671.html" rel="external">picture 2</a>) [<a href="#rid23">23</a>]. Major findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>The most common morphologic finding was a lymphoid infiltration of nodular B-cell aggregates, seen in 40 of the 54 (74 percent); the remaining 14 had scattered B cells  (<a class="graphic graphic_picture graphicRef119671" href="/z/d/graphic/119671.html" rel="external">picture 2</a>). Mature plasma cells were sometimes seen surrounding the aggregates as well as throughout the bone marrow, but the number of plasma cells generally was not increased (range, 2 to 10 percent of nucleated cells). Immunophenotyping demonstrated that the lymphocytes were mostly B cells expressing IgM with a kappa light chain, and the plasma cells expressed IgM with kappa light chains. The predominant immunophenotype was positive for CD19, CD20, CD22, CD79b, and FMC7; CD23 was negative and CD5 was seen in less than one-half of the cases. In the 14 individuals who did not have lymphoid aggregates, flow cytometry on blood or bone marrow demonstrated a monoclonal population of B cells with similar features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast to lymphoplasmacytic lymphoma (LPL; the underlying bone marrow finding in Waldenström macroglobulinemia [WM]), there was no characteristic LPL morphology; there was no increase in mast cells, paratrabecular growth, or fibrosis; and the testing for the <em>MYD88</em> L265P mutation, commonly seen in LPL, was negative in all 17 cases tested. (See  <a class="medical medical_review" href="/z/d/html/4768.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the immunophenotype was similar to extranodal or nodal marginal zone lymphoma, none of the patients had extramedullary disease.</p><p></p><p>Separate studies evaluating genetic changes have found the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Exome sequencing or targeted sequencing of selected genes in B cells isolated from the bone marrows of 16 individuals with primary CAD using exome sequencing of bone marrow-derived B cells in six and targeted sequencing of selected genes in the remaining 10 identified variants in <em>KMT2D</em> in 11 (69 percent) and variants in <em>CARD11</em> in five (31 percent); four of these also had a <em>KMT2D</em> variant [<a href="#rid4">4</a>]. Inactivating <em>KMT2D</em> mutations are also seen in certain lymphomas. Use of histone deacetylase (HDAC) inhibitors in the treatment of these lymphomas, as well as in Kabuki syndrome (germline pathogenic variant in the <em>KMT2D</em> gene) is under study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytogenetic analysis of 15 samples of bone marrow-derived B cells identified complete or partial gain of chromosome 3 in 14 (93 percent), along with gain of chromosome 12 or 18 in 11 (73 percent) [<a href="#rid33">33</a>]. These changes are similar to those seen in marginal zone lymphoma (MZL). Although numbers were small, chromosome 18 gains appeared to be associated with decreased response to therapy, also similar to MZL.</p><p></p><p>The likelihood of progression to a malignant lymphoid neoplasm is unknown, but in most cases, the cold agglutinin persists without change for a number of years. The frequency of transformation to an aggressive lymphoma is very low (probably 3 to 4 percent over 10 years) [<a href="#rid12">12,34</a>]. </p><p class="headingAnchor" id="H1828475011"><span class="h2">Mechanism of hemolysis</span><span class="headingEndMark"> — </span>Hemolysis in CAD is primarily extravascular and mediated by complement. The following sequence of events is thought to be most typical [<a href="#rid17">17,35,36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The IgM cold agglutinin binds to its cognate antigen (usually "I" or "i") on the surface of RBCs in sites of the body where the temperature is low enough to be in the thermal range of the antibody (eg, acral areas, especially with cold ambient temperatures). (See <a class="local">'RBC antigens'</a> above and <a class="local">'Cold agglutinins'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The bound IgM recruits components of the classical pathway of complement, such as C1, C4, and C2 [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'Pathways and activating conditions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C1-esterase activates C4 and C2, leading to production of the C3 convertase, which cleaves C3 to C3a and C3b, as illustrated in the figure  (<a class="graphic graphic_figure graphicRef56374" href="/z/d/graphic/56374.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">"Complement pathways", section on 'Classical pathway'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C3b-coated RBCs are phagocytosed by macrophages in the reticuloendothelial system (ie, extravascular hemolysis), predominantly Kupffer cells in the liver [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Extravascular hemolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Phagocytes tend to engulf the entire cell rather than a portion of the cell membrane, as occurs in phagocytosis mediated by IgG. This may explain the absence of spherocytosis in CAD (or a relatively less impressive spherocytosis), compared with warm autoimmune hemolytic anemia (AIHA). (See <a class="local">'CBC, blood smear, and hemolysis testing'</a> below.)</p><p></p><p>On the remaining circulating RBCs (ie, those that are not phagocytosed), IgM dissociates upon warming, but C3b remains attached. Surface C3b undergoes cleavage to C3d, which can be detected by the direct antiglobulin (Coombs) test [<a href="#rid36">36</a>]. A positive Coombs test for complement is one of the initial findings that suggests CAD, as discussed below. (See <a class="local">'CBC, blood smear, and hemolysis testing'</a> below.)</p><p>Typically, complement inhibitors such as CD55 and CD59 on the RBC surface prevent the classical complement pathway from activating the terminal cascade, in which the membrane attack complex (MAC; C5b-9) lyses the cells intravascularly. However, when hemolysis is especially brisk (eg, with concomitant infection, surgery, or other inflammatory states), a component of intravascular hemolysis may occur [<a href="#rid36">36</a>]. In these cases, patients may have hemoglobinuria, which occurred in 15 percent of patients in one series [<a href="#rid35">35</a>]. In other rare cases, an IgG warm-reactive antibody may accompany the IgM cold agglutinin (so-called "mixed" autoimmune hemolytic anemia); this may lead to more severe hemolysis including an intravascular component [<a href="#rid39">39,40</a>]. (See <a class="local">'CBC, blood smear, and hemolysis testing'</a> below.)</p><p>Studies of the in vitro properties of cold agglutinins in several patients with CAD have determined that the severity of hemolysis correlated most closely with properties of the antibody (eg, avidity for RBC membrane, ability to fix complement, thermal amplitude) rather than cold agglutinin titer [<a href="#rid16">16,38,41,42</a>].</p><p class="headingAnchor" id="H8773186"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary CAD is rare. In retrospective reviews from Nordic countries, the incidence has been estimated at approximately 1 to 1.8 per million and the prevalence at approximately 13 to 16 per million [<a href="#rid12">12,43</a>]. A series that included nearly all affected individuals in Norway and Lombardy (North Italy) found prevalences of approximately 20 per million and 5 per million, respectively, suggesting a fourfold higher prevalence in colder climates; the mean temperature in Norway is 7°C colder than North Italy [<a href="#rid34">34</a>]. </p><p>Studies have also demonstrated a slightly higher prevalence in females and a median age of diagnosis in the late 60s to early 70s. (See <a class="local">'Clinical manifestations'</a> below.)</p><p>CAD is significantly less common than warm autoimmune hemolytic anemia (warm AIHA), accounting for approximately one-fifth to one-quarter of patients with AIHA in retrospective series [<a href="#rid40">40,44</a>].</p><p>The prevalence of secondary cold agglutinin syndrome in individuals with underlying infection or lymphoid malignancies estimated from case series includes:</p><p class="bulletIndent1"><span class="glyph">●</span>In 496 individuals with <em>M. pneumoniae </em>infection in Denmark, 407 (82 percent) had in vitro evidence of cold agglutinins; however, these were not associated with clinical symptoms or hemolysis, and it is likely that the majority of cold agglutinins were clinically silent [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 217 individuals with Waldenström macroglobulinemia (WM), 5 percent had cold agglutinins, but only 1.5 percent had hemolysis [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H3155709169"><span class="h1">ASSOCIATED DISORDERS</span></p><p class="headingAnchor" id="H739140331"><span class="h2">Likelihood of an associated disorder</span><span class="headingEndMark"> — </span>The likelihood that a person with cold agglutinin-mediated autoimmune hemolytic anemia (AIHA) has an underlying disorder depends on their age and the extent of the evaluation performed. Younger patients may be more likely to have an underlying infection or autoimmune disorder, and older individuals (eg, &gt;60 years of age) may be more likely to have a lymphoid (B-cell or plasma cell) malignancy such as aggressive non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM).</p><p>There is also a sizeable group of patients with no evidence of lymphoma who have a monoclonal cold agglutinin. Most if not all of these individuals probably have a low-grade lymphoproliferative disorder responsible for the production of a monoclonal cold agglutinin [<a href="#rid47">47</a>]. (See <a class="local">'Primary CAD-associated lymphoproliferative disorder'</a> above.)</p><p>Although cold agglutinins have been reported in individuals with solid tumors, this likely represents an incidental association rather than a causal relationship [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2329708403"><span class="h2">Infections and autoimmune disorders</span><span class="headingEndMark"> — </span>Cold agglutinins regularly occur during the course of two infections:</p><p class="bulletIndent1"><span class="glyph">●</span><em>M. pneumoniae</em> (primary atypical pneumonia) [<a href="#rid49">49-51</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Epstein-Barr virus (infectious mononucleosis) [<a href="#rid52">52</a>]</p><p></p><p>Case reports have described cold agglutinins in the setting of other viral infections such as human immunodeficiency virus (HIV), rubella virus, influenza viruses, coronavirus disease 2019 (COVID-19) infection, or varicella-zoster virus (chickenpox) [<a href="#rid45">45,53-56</a>].</p><p>Not all individuals with these infections who develop cold agglutinins will have clinically significant hemolysis. For those who do, it usually occurs approximately two weeks after onset of the primary infection, diminishes as the infection begins to resolve, and is gone within two to three months.</p><p>Cold agglutinins have also been described in individuals with autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis [<a href="#rid57">57,58</a>].</p><p class="headingAnchor" id="H1519577755"><span class="h2">Lymphoproliferative disorders</span><span class="headingEndMark"> — </span>The association with B-cell or plasma cell lymphoproliferative disorders has been illustrated in several case series. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a 2020 series of 232 patients with primary CAD, review by unselected pathologists identified the following clonal lymphoproliferative disorders [<a href="#rid34">34</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CAD-associated lymphoproliferative disorder – 27 percent </p><p class="bulletIndent2"><span class="glyph">•</span>Lymphoplasmacytic lymphoma (the lymphoma seen in Waldenström macroglobulinemia [WM]) – 14 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Marginal zone lymphoma – 4 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Small lymphocytic lymphoma – 4 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Unclassified lymphoproliferation or reactive lymphocytosis – 18 percent</p><p></p><p class="bulletIndent1">The remaining 31 percent were classified as having no bone marrow lymphoproliferation [<a href="#rid34">34</a>]. Following centralized biopsy review by pathologists with experience in CAD pathology, however, the percentage of patients with identifiable CAD-associated lymphoproliferative disorder increased to 76 percent; percentages of patients diagnosed with other lymphoproliferative disorders decreased correspondingly, while only 13 percent had no histopathologic signs of clonal lymphoproliferation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2013 series of 89 patients diagnosed with CAD (median age, 65 years), lymphoid disorders were present in approximately 78 percent [<a href="#rid35">35</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monoclonal gammopathy of undetermined significance (MGUS) – 47 percent </p><p class="bulletIndent2"><span class="glyph">•</span>Other non-Hodgkin B-cell lymphoma – 9 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Unspecified lymphoproliferative disorder – 9 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Chronic lymphocytic leukemia (CLL) – 4 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a 2014 series of 20 patients with CAD, all had a clonal lymphoproliferative disorder [<a href="#rid47">47</a>].</p><p></p><p>Cold agglutinin-mediated hemolytic anemia associated with a clinically overt B-cell lymphoma is now referred to as a separate entity, (secondary) cold agglutinin syndrome (CAS) [<a href="#rid2">2,59,60</a>]. (See <a class="local">'Terminology and distinction among syndromes'</a> above.)</p><p class="headingAnchor" id="H2294322589"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H1024438745"><span class="h2">Overview of typical findings</span><span class="headingEndMark"> — </span>The mean age at presentation of CAD is in the mid to late 60s, with a broad range (30s to 90s) [<a href="#rid12">12,34,35</a>].</p><p>In many cases, individuals with circulating cold agglutinins may be unaware of the presence of these antibodies unless or until they are exposed to cold temperatures that enhance antibody binding to red blood cells (RBCs). In countries with cool or temperate climates, CAD is diagnosed more frequently during the cold seasons [<a href="#rid61">61</a>]. </p><p>However, when the disease is diagnosed, clinical and hematologic manifestations seem to persist year-round [<a href="#rid62">62</a>]. Cases of catastrophic hemolysis and organ failure have been described in cardiac surgery involving hypothermia (eg, for cardiopulmonary bypass) [<a href="#rid63">63</a>]. On the other hand, it is important to emphasize that not all individuals with demonstrable cold agglutinins have a cold agglutinin-related disease. In one series, for example, cold agglutinins were found in 0.3 percent of individuals with unrelated disorders [<a href="#rid64">64</a>].</p><p>The largest published series, involving 232 affected individuals, reported the following likelihoods of common findings [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia (median hemoglobin, 9.5 g/dL) – 90 percent (compensated hemolysis in the remainder)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic markers (high lactate dehydrogenase [LDH] and bilirubin, low haptoglobin) – approximately 90 percent each</p><p class="bulletIndent1"><span class="glyph">●</span>Cold-induced symptoms (mostly acrocyanosis) – 52 percent</p><p></p><p>More severe cold-induced symptoms such as Raynaud phenomenon or ulceration were seen in a smaller proportion. Fatigue is a well-recognized symptom that may be caused by the anemia as well as by complement activation alone, although the exact frequency is unknown [<a href="#rid65">65</a>]. Transfusions were given, either preceding diagnosis or during follow-up, in 38 to 47 percent [<a href="#rid34">34</a>]. During follow-up, 3.4 percent developed diffuse large B cell lymphoma (DLBCL). (See <a class="local">'Lymphoproliferative disorders'</a> above.)</p><p class="headingAnchor" id="H3611761555"><span class="h2">Cold-induced symptoms (eg, acrocyanosis and Raynaud phenomenon)</span><span class="headingEndMark"> — </span>Cold-induced symptoms in the acral areas are extremely common in CAD, affecting approximately 90 percent of individuals who live in colder climates such as in Scandinavia [<a href="#rid12">12,34</a>]. These symptoms can range from mild to disabling and include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Acrocyanosis (dark purple-to-gray discoloration of the skin in acral areas such as fingertips, toes, nose, and ears)</p><p class="bulletIndent1"><span class="glyph">●</span>Livido reticularis (a blanchable, patchy, reticulated vascular pattern on the skin with a red-blue or violaceous color)  (<a class="graphic graphic_picture graphicRef61212" href="/z/d/graphic/61212.html" rel="external">picture 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Raynaud phenomenon (sharply demarcated color changes of the skin of the digits)  (<a class="graphic graphic_picture graphicRef66438" href="/z/d/graphic/66438.html" rel="external">picture 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous ulceration or even necrosis in severe cases [<a href="#rid66">66-69</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Pain or discomfort on swallowing cold food or liquids</p><p></p><p>As noted above, these symptoms are related to RBC agglutination by IgM that bind to their surface in the cold (see <a class="local">'Cold agglutinins'</a> above). They disappear upon warming, and there is often little or no reactive hyperemia that is sometimes seen in the reperfusion phase of Raynaud phenomena. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Hemolytic anemia (Coombs-positive for complement)</span><span class="headingEndMark"> — </span>Hemolysis (extravascular) is common in CAD. The severity can range from compensated hemolysis without anemia to severe hemolytic anemia requiring transfusion [<a href="#rid9">9,34</a>]. Some individuals have chronic compensated hemolytic anemia with episodes of more severe anemia due to increased hemolysis precipitated by cold temperatures or inflammatory responses.</p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of hemolysis may be precipitated by exposure to colder ambient temperatures, as illustrated in a case report of a road worker with CAD who was outside during the days and had clearly documented seasonal hemolysis [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Episodes of hemolysis may also be exacerbated by febrile or other acute illnesses, as illustrated in a one-year prospective study of an individual who was generally in good health but developed hemolysis several times during a one-year period of observation that correlated with episodes of the common cold, pneumonia, and hip fracture [<a href="#rid71">71</a>]. A study of 15 individuals with chronic CAD found hemolysis during episodes of fever in five (one-third) participants.</p><p></p><p>Median hemoglobin levels in the larger case series are approximately 9 to 10 g/dL, with some individuals in the normal range and others as low as 4.5 g/dL [<a href="#rid12">12,34,35</a>]. In a large series of 232 individuals, 25 to 30 percent had a hemoglobin &lt;8 g/dL [<a href="#rid34">34</a>].</p><p>Symptoms attributable to anemia may occur, often in proportion to the severity of the anemia and the rapidity of its development. These may include exertional dyspnea, dyspnea at rest, varying degrees of fatigue, and signs and symptoms of the hyperdynamic state. Some individuals may develop jaundice or mild splenomegaly related to hemolysis.</p><p>Laboratory findings are consistent with autoimmune, extravascular hemolysis mediated by the classical complement activation pathway. (See <a class="local">'CBC, blood smear, and hemolysis testing'</a> below.)</p><p class="headingAnchor" id="H2406876232"><span class="h2">Fatigue</span><span class="headingEndMark"> — </span>Many patients with CAD experience fatigue, which does not seem to be exclusively related to the degree of anemia but can also be caused directly by activation of the complement system with generation of proinflammatory, soluble split products [<a href="#rid1">1,3,65,72,73</a>]. The exact frequency has not been determined.</p><p class="headingAnchor" id="H2189938484"><span class="h2">Venous thromboembolism</span><span class="headingEndMark"> — </span>In a series of 72 individuals diagnosed with CAD from Denmark, an increased rate of venous thromboembolism (VTE) was observed as compared with age- and sex-matched controls [<a href="#rid43">43</a>]. The risk was not statistically significant and there were some methodology issues. A significant risk of VTE has been demonstrated, however, in subgroups with severe hemolysis [<a href="#rid74">74</a>]. </p><p>A retrospective study involving a cohort of 608 individuals diagnosed with CAD from an insurance-based registry and nearly 6000 matched controls recorded thromboembolic events during a 10-year period (venous and arterial) in 30 percent of those with CAD versus 18 percent of controls (adjusted hazard ratio [HR] 3.1, 95% CI 2.24-4.30) [<a href="#rid75">75</a>]. A possible risk of arterial thrombosis is more controversial.</p><p>We do not routinely administer prophylactic anticoagulation to reduce the risk, but anticoagulation should be considered in acute exacerbations and if additional risk factors are present [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H1212923160"><span class="h2">When to suspect CAD</span><span class="headingEndMark"> — </span>Delays in diagnosis are common, with a delay of one or more years between symptom onset and diagnosis in many cases [<a href="#rid34">34,35</a>]. </p><p>Any patient with autoimmune hemolytic anemia (AIHA) should have a sufficient diagnostic workup to establish the subtype, including the possibility of CAD. (See  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p>In particular, primary CAD or secondary cold agglutinin syndrome (CAS) may be suspected in an individual with cold-induced symptoms (eg, pain and discomfort in the extremities with exposure to cold or on swallowing cold liquids or foods). CAD or CAS may also be suspected in a person with unexplained hemolytic anemia or red blood cell (RBC) agglutination in a cooled blood collection tube or on the peripheral blood smear. A clue to the latter may be a very high mean corpuscular volume (MCV), a spurious result caused by RBC agglutination.</p><p>The suspicion for secondary CAS is increased in the setting of an infectious disease, autoimmune syndrome, or lymphoproliferative disorder. (See <a class="local">'Associated disorders'</a> above.)</p><p class="headingAnchor" id="H64386682"><span class="h2">CBC, blood smear, and hemolysis testing</span><span class="headingEndMark"> — </span>The typical diagnostic approach in any suspected hemolytic anemia generally starts with a complete blood count (CBC) and review of the RBC indices and/or the peripheral blood smear. This may be followed by testing for hemolysis including haptoglobin, lactate dehydrogenase (LDH), indirect bilirubin, and direct antiglobulin (Coombs) testing (DAT).</p><p>Findings consistent with CAD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CBC</strong> – Anemia (may be absent if hemolysis is mild and/or reticulocytosis is sufficient to compensate).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The MCV may be low, normal, or high depending on the degree of reticulocytosis and RBC agglutination.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spurious macrocytosis can also occur if the sample is cooled during processing or when it passes through the automated analyzer [<a href="#rid76">76,77</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The white blood cell (WBC) count and platelet count are typically normal, although there may be leukocytosis or leukopenia if there is an infection or bone marrow disorder.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If agglutination takes place in the CBC sample prior to analysis, the RBC count may be artifactually low due to microaggregates, and there may be an inappropriately high MCV, depending on the type of analyzer. These abnormal results resolve if the sample is re-run after pre-warming [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood smear</strong> – RBC agglutination  (<a class="graphic graphic_picture graphicRef50522" href="/z/d/graphic/50522.html" rel="external">picture 1</a>) may be apparent (occasionally this can be seen in the collection tube  (<a class="graphic graphic_picture graphicRef116213" href="/z/d/graphic/116213.html" rel="external">picture 5</a>)); spherocytes may be present but are usually not abundant.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reticulocyte count</strong> – Usually, the reticulocyte count is increased if there is ongoing (chronic) hemolysis. The reticulocyte count may be normal if hemolysis has just occurred and there has been insufficient time for reticulocytes to appear in the peripheral blood; if there is an underlying bone marrow disorder that interferes with compensatory erythropoiesis; or if the autoantibody binds to RBC precursors as well as mature RBCs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LDH, bilirubin, haptoglobin</strong> – When hemolysis is present, the LDH and bilirubin are increased and the haptoglobin is decreased or absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coombs</strong> <strong>test</strong> – The direct Coombs test (DAT) is positive for the complement component C3d and generally negative for immunoglobulin; a polyspecific Coombs test will be positive. If an IgG antibody accompanies the cold agglutinin, the Coombs test may also be weakly positive for IgG; this has been reported in up to one-quarter of patients [<a href="#rid12">12,35</a>].</p><p></p><p class="bulletIndent1">Not all RBC antibodies cause hemolysis, and an A positive DAT in the absence of hemolysis is not sufficient to make the diagnosis of CAD [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement levels (not helpful)</strong> – Complement C3 and, in particular, C4 levels are often reduced, reflecting a continuous consumption [<a href="#rid12">12</a>]. However, serum complement levels generally are not helpful in the evaluation for CAD, as they are relatively nonspecific and may depend on the patient's clinical status.</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Antibody titer and thermal amplitude</span><span class="headingEndMark"> — </span>Cold agglutinin titer should be measured in all patients with suspected CAD; thermal amplitude is generally restricted to complex management cases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Titer</strong> – The cold agglutinin titer reflects the strength (concentration and avidity) of the antibody. Titer is determined by testing serial dilutions of patient serum for their ability to agglutinate RBCs. The titer is the highest dilution at which cold-induced agglutination of RBCs occurs.</p><p></p><p class="bulletIndent1">Typical cold agglutinin titers in CAD are quite high. The accepted threshold for diagnosis is 64, and most experts consider a titer above 512 to be clinically significant; in many cases the titer is greater than 2048 [<a href="#rid35">35</a>]. Titers lower than this are very unlikely to be clinically significant; up to 95 percent of healthy blood donors in one study had cold agglutinin titers ≤4 [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thermal properties</strong> – The cold agglutinin thermal range reflects the temperature range over which the antibody will bind to the RBC antigen. The thermal amplitude (TA) is the highest temperature at which the antibody will bind the antigen. Most clinically significant cold agglutinins have a thermal amplitude that exceeds 28 to 30°C [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">TA is more important for clinical manifestations than titer but more difficult to measure in the laboratory [<a href="#rid9">9</a>]. Thus, we typically obtain TA testing once at the initial assessment to determine its clinical importance, but we do not use it to guide therapy. TA testing is especially important for complex cases in which initial testing is indeterminate or for surgical planning for individuals undergoing procedures with planned cardioplegia, so that the patient's body temperature can be maintained above the TA. The most important reading for the TA is the presence of agglutination at body temperature.</p><p></p><p>Importantly, care must be taken in collecting blood for cold agglutinin analysis. The specimen must be maintained at 37 to 40°C until the clot has formed and retracted and the serum has been removed; otherwise, the cold agglutinin may precipitate and be inadvertently removed from the sample during serum preparation.</p><p class="headingAnchor" id="H3989574490"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Generally accepted diagnostic criteria include the following [<a href="#rid9">9,80,81</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of hemolysis (eg, high reticulocyte count, high LDH, high indirect bilirubin, low haptoglobin)</p><p class="bulletIndent1"><span class="glyph">●</span>Positive direct antiglobulin (Coombs) test for C3d only (or, in a minority, C3d plus weak IgG)</p><p class="bulletIndent1"><span class="glyph">●</span>Cold agglutinin titer of ≥64 at 4°C</p><p></p><p>Caveats about sample handling are noted above. (See <a class="local">'Antibody titer and thermal amplitude'</a> above.)</p><p class="headingAnchor" id="H4198478912"><span class="h2">Testing for underlying disorders</span><span class="headingEndMark"> — </span>Evaluation for an underlying disorder that could be responsible for cold agglutinins is appropriate in most individuals, especially older adults and those who have evidence of an infectious, autoimmune, or lymphoproliferative disorder [<a href="#rid9">9</a>]. (See <a class="local">'Associated disorders'</a> above.)</p><p>In some cases, a thorough history and physical examination is sufficient. Additional studies (laboratory testing and/or radiologic imaging) such as the following are often indicated:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Testing for an infectious disorder is appropriate in those with fever and/or respiratory symptoms, particularly if the duration of symptoms is short. Testing for infectious mononucleosis is especially relevant in a child or young adult. Testing for mycoplasma is especially relevant in an individual with atypical pneumonia. (See  <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">"Infectious mononucleosis"</a> and  <a class="medical medical_review" href="/z/d/html/6070.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmune disorder</strong> – Testing for an autoimmune disorder is reasonable in those with arthralgias or arthritis, malar rash, or cytopenias. This may include serologies for systemic lupus erythematosus (SLE) or others depending on the clinical presentation. (See <a class="local">'Infections and autoimmune disorders'</a> above and  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphoproliferative disorder or lymphoid malignancy</strong> – Testing for a lymphoproliferative disorder or lymphoid malignancy (eg, non-Hodgkin lymphoma or Waldenström macroglobulinemia [WM]) is done if there is weight loss, lymphadenopathy, hepatosplenomegaly, lymphocytosis, and/or cytopenias; in an older individual without evidence of infection or autoimmune disease; or in any patient with chronic hemolysis from a cold agglutinin. Details of testing are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a> and  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="bulletIndent1">Most individuals who have chronic primary CAD likely have a very indolent lymphoproliferative disorder in the bone marrow, especially those with a kappa-restricted IgM cold agglutinin with a high titer. Details of the immunophenotype and genetic changes are discussed above. (See <a class="local">'Cold agglutinins'</a> above and <a class="local">'Primary CAD-associated lymphoproliferative disorder'</a> above.)</p><p></p><p>The results of this evaluation have important implications for therapy, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Most cold agglutinins that are associated with infections or autoimmune disorders are likely to be polyclonal and to resolve spontaneously with resolution of the infection (which may include antibiotic therapy) or treatment of the autoimmune disorder. These patients can be advised to avoid cold temperatures until they recover. (See <a class="local">'Cold avoidance'</a> below.)</p><p></p><p class="bulletIndent1">In severe cases with significant hemolytic anemia, patients must be kept under close observation until the hemolysis has resolved. It is possible that treatments directed at the reticuloendothelial clearance of the cold agglutinins (eg, glucocorticoids, splenectomy) may be somewhat effective, especially if there is mixed warm and cold autoimmune hemolytic anemia (AIHA).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cold agglutinins associated with lymphoid malignancies or chronic CAD associated with a lymphoproliferative disorder in the bone marrow are very likely to be monoclonal and will <strong>not</strong> resolve spontaneously or respond to glucocorticoids or splenectomy. If these individuals have significant hemolysis, treatment will require a therapy to eradicate the clone of cells producing the cold agglutinin. (See <a class="local">'Therapies directed at the pathogenic process'</a> below.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of CAD and secondary cold agglutinin syndrome (CAS) includes other causes of cold-induced symptoms and other hemolytic anemias. The table summarizes differences among the antibody-mediated conditions that are activated by cold temperature  (<a class="graphic graphic_table graphicRef103370" href="/z/d/graphic/103370.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold-induced symptoms</strong> – Other causes of cold-induced symptoms include primary Raynaud phenomenon, Raynaud phenomenon associated with other underlying disorders, and cryoglobulinemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary and other secondary Raynaud phenomenon</strong> – Raynaud phenomenon can be caused by a number of conditions including CAD and secondary CAS. Unlike patients with CAD or secondary CAS, individuals with these other disorders have no evidence of a cold agglutinin on the blood smear or laboratory testing, and in many cases, these individuals do not have autoimmune hemolytic anemia (ie, they have a negative Coombs test). Evaluation of Raynaud phenomenon is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cryoglobulinemia</strong> – Cryoglobulins are immune complexes that form in cold temperatures and can cause a number of findings including arthralgias, purpura, skin ulcers, glomerulonephritis, or peripheral neuropathy. Like CAD or secondary CAS, individuals with certain types of cryoglobulinemia (especially type I and mixed cryoglobulinemias) can have cold-induced Raynaud phenomenon, and they may have a history of an infection (often, hepatitis C virus [HCV]), a monoclonal gammopathy, or an autoimmune disorder. Unlike patients with CAD or secondary CAS, individuals with cryoglobulinemia have no evidence of a cold agglutinin on laboratory testing, and in many cases these individuals do not have autoimmune hemolytic anemia (AIHA; ie, they have a negative Coombs test). (See  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a> and  <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemolytic anemia</strong> – Other causes of hemolytic anemia include warm AIHA, drug-induced hemolytic anemia, hemolytic transfusion reactions (HTRs), and paroxysmal cold hemoglobinuria (PCH). Differences in the findings of direct antiglobulin testing (DAT; Coombs testing) in these conditions are summarized in the table  (<a class="graphic graphic_table graphicRef128183" href="/z/d/graphic/128183.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Warm AIHA and drug-induced hemolytic anemia</strong> – Warm AIHA is the most common type of immune hemolytic anemia. Like CAD or secondary CAS, in warm AIHA and some forms of drug-induced hemolysis, there is usually evidence of extravascular immune hemolysis (eg, high lactate dehydrogenase [LDH] and indirect bilirubin, low haptoglobin, increased reticulocyte count, positive Coombs test). Unlike CAD or secondary CAS, in warm AIHA and drug-induced hemolytic anemia, there are usually no cold-induced symptoms, the Coombs test is positive for IgG rather than complement, and the blood smear shows spherocytes but no red blood cell (RBC) agglutination  (<a class="graphic graphic_table graphicRef128183" href="/z/d/graphic/128183.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Paroxysmal cold hemoglobinuria</strong> – PCH is a cold-induced autoimmune hemolytic anemia associated with an IgG antibody, usually with anti-P specificity; a positive Donath-Landsteiner test; and, frequently, a recent history of a viral infection. The Coombs test may be positive for bound complement, but the cold agglutinin titer is, at most, only moderately elevated (ie, &lt;160). (See  <a class="medical medical_review" href="/z/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemolytic transfusion reactions</strong> – HTRs can be acute or delayed. Both types of HTRs are caused by alloantibodies that react with antigens on the transfused RBCs. Like CAD and secondary CAS, HTRs can show findings of immune hemolysis. Unlike CAD and secondary CAS, HTRs do not have cold-induced symptoms or red cell agglutination, and laboratory evaluation of an HTR will reveal the relevant RBC antigen in the transfused unit. (See  <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">"Hemolytic transfusion reactions"</a>.)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H16493609"><span class="h2">Overview of the approach to treatment</span><span class="headingEndMark"> — </span>Not all individuals with cold agglutinins have clinical manifestations, and asymptomatic patients have not been shown to benefit from therapy. </p><p>We consider symptomatic anemia, significant fatigue, or bothersome circulatory symptoms as indications for treatment [<a href="#rid1">1,82</a>]. Treatment aims at minimizing symptoms, maintaining an acceptable hemoglobin level, and, if required, addressing underlying disorders [<a href="#rid9">9,83</a>].</p><p>Major treatment decisions are summarized in the flowchart  (<a class="graphic graphic_algorithm graphicRef138277" href="/z/d/graphic/138277.html" rel="external">algorithm 1</a>). </p><p>In a retrospective series of 232 individuals, 175 (76 percent) had received CAD-directed medical therapy, whereas the remaining 24 percent were treated with supportive/symptomatic care alone [<a href="#rid34">34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold-induced symptoms</strong> – The main therapy is avoidance of cold temperatures (see <a class="local">'Cold avoidance'</a> below). For those with chronic or severe symptoms and a monoclonal cold agglutinin, therapy directed at the underlying clone is usually appropriate. (See <a class="local">'Therapies directed at the pathogenic process'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia</strong> – Compensated hemolysis or hemolysis with mild, stable anemia may not require specific treatment. For individuals with severe or symptomatic anemia, transfusions can be given, and plasmapheresis may be used as a temporizing measure. Therapy to reduce antibody production is indicated in these individuals. (See <a class="local">'Emergency and supportive therapies for anemia'</a> below and <a class="local">'Therapies directed at the pathogenic process'</a> below and <a class="local">'Anti-complement therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying disorders</strong> – Management is individualized according to the specific disorder and patient's clinical status. If no underlying disorder is found in an individual with chronic CAD, the disorder is presumed to be due to a low-grade lymphoproliferative disorder (ie, a very indolent clone that may or may not progress to a lymphoid malignancy), and antibody production is usually targeted with a rituximab-containing regimen. (See <a class="local">'Associated disorders'</a> above and <a class="local">'Therapies directed at the pathogenic process'</a> below.)</p><p></p><p>Patients with CAD requiring therapy should be considered for inclusion in prospective trials if available. </p><p class="headingAnchor" id="H17"><span class="h2">Cold avoidance</span><span class="headingEndMark"> — </span>Cold avoidance is used to reduce cold-induced symptoms and hemolysis.</p><p class="headingAnchor" id="H177705236"><span class="h3">Ambulatory patients</span><span class="headingEndMark"> — </span>Avoidance of cold demands constant vigilance to avoid cold rooms or environments, cold water (eg, in public sinks), and cold liquids that may be served in public restaurants. Space heaters may be necessary to keep room temperature at adequate levels.</p><p>Outdoors (or in cold indoor spaces), warm clothing should protect acral areas; this includes warm shoes, stockings, gloves, and scarves or earmuffs that protect the extremities, nose, and ears. It may be useful to avoid cold foods or liquids if these cause symptoms.</p><p>Some individuals who live in cold parts of the world may be able to spend colder months in a more temperate region. Accommodations should be made for those with jobs that include cold exposure.</p><p class="headingAnchor" id="H62379160"><span class="h3">Hospitalized patients</span><span class="headingEndMark"> — </span>Avoidance of cold is especially important during hospitalization and surgery, when the affected individual may have less control over their ambient temperature and the temperature of intravenous solutions [<a href="#rid9">9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous solutions and blood products should be warmed to an appropriate temperature before infusion. For blood transfusions, the temperature must be warm but cannot be above 40°C. (See <a class="local">'Transfusions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Space heaters and blanket should be provided as needed, and liquids without ice should be available for drinking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fever should be treated with antipyretics and prompt treatment of infections rather than with cooling blankets [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If any hypothermic surgical procedures are required, advance multidisciplinary planning should include input from the consulting hematologist, laboratory medicine service, anesthesiologist, and surgeon regarding precautions to prevent acute hemolytic crisis in the operating room. (See  <a class="medical medical_review" href="/z/d/html/140569.html" rel="external">"Cardiac surgery with cardiopulmonary bypass in patients with cold agglutinin disease", section on 'Cold agglutinins versus cold agglutinin disease'</a>.)</p><p></p><p class="bulletIndent1">This may include preoperative testing to characterize the thermal amplitude of the cold agglutinin, plasmapheresis, and/or warm cardioplegia [<a href="#rid85">85-88</a>]. Prophylactic use of <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">eculizumab</a> or <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> in this situation has been described in case reports [<a href="#rid89">89,90</a>]. (See <a class="local">'Antibody titer and thermal amplitude'</a> above and <a class="local">'Plasmapheresis or IVIG as a temporizing measure'</a> below and  <a class="medical medical_review" href="/z/d/html/140569.html" rel="external">"Cardiac surgery with cardiopulmonary bypass in patients with cold agglutinin disease", section on 'Cold agglutinins versus cold agglutinin disease'</a>.)</p><p></p><p class="headingAnchor" id="H2901545616"><span class="h2">Emergency and supportive therapies for anemia</span></p><p class="headingAnchor" id="H3673584236"><span class="h3">Complement inhibition</span><span class="headingEndMark"> — </span>Upstream complement inhibition may be used instead of plasmapheresis in the emergency setting, given the very rapid effect of complement C1 inhibition on hemolysis in CAD and the relatively weak evidence supporting plasmapheresis [<a href="#rid65">65,91</a>]. </p><p>The C1s inhibiting monoclonal antibody <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> is preferred if available [<a href="#rid65">65</a>]. Even C5 inhibition may be helpful, as cleavage of C5 with terminal complement activation and intravascular hemolysis can be significant in profoundly anemic patients [<a href="#rid74">74</a>]. (See <a class="local">'Anti-complement therapies'</a> below.)</p><p class="headingAnchor" id="H2114858370"><span class="h3">Plasmapheresis or IVIG as a temporizing measure</span><span class="headingEndMark"> — </span>For critical hemolysis when the delay of several weeks to days before immunosuppressive therapy takes effect is unacceptable, plasmapheresis or intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG) may be used  (<a class="graphic graphic_algorithm graphicRef138277" href="/z/d/graphic/138277.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasmapheresis</strong> – Plasmapheresis is thought to be highly effective in removing cold agglutinins because these are almost always IgM antibodies that are distributed almost entirely intravascularly. (See <a class="local">'Cold agglutinins'</a> above.)</p><p></p><p class="bulletIndent1">There have been no large trials or series to assess the efficacy of plasmapheresis in CAD, but case reports have described reduction of hemolysis and in one case, improvement in severe acrocyanosis [<a href="#rid11">11,92</a>]. Therapeutic apheresis for severe CAD is considered a category II indication by the American Society for Apheresis. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'ASFA therapeutic categories'</a>.)</p><p></p><p class="bulletIndent1">While plasmapheresis can remove IgM, it does nothing to decrease IgM production and thus must be seen as a temporizing measure to be used only until other therapies become effective. The optimal exchange volume and number of exchange procedures remain unproven; 1 to 1.5 times the plasma volume per exchange seems reasonable [<a href="#rid2">2,81</a>]. Albumin should be used as the exchange fluid instead of plasma, both to avoid exacerbating the disease by providing additional complement as well as to reduce plasma-related adverse effects [<a href="#rid71">71,81</a>]. (See  <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">"Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology", section on 'Replacement fluids'</a>.)</p><p></p><p class="bulletIndent1">The procedure should be performed in a warm environment and precautions taken to prevent cooling, which could exacerbate cold symptoms and hemolysis [<a href="#rid93">93</a>]. Since apheresis does not address the source of antibody production, it is essential that therapy to address the underlying cause is initiated as soon as possible (see <a class="local">'Therapies directed at the pathogenic process'</a> below). If performed to prepare a patient for surgery, it should be performed no more than one to two days before the procedure, so that the antibody does not re-accumulate [<a href="#rid92">92</a>]. After removal, the half-life for re-accumulation of the IgM is approximately five days.</p><p></p><p class="bulletIndent1">Cryofiltration apheresis (CFA) is a form of plasmapheresis that allows removal of the cold agglutinins without removal of other plasma proteins, and thus it does not require a replacement fluid such as donor plasma or albumin [<a href="#rid94">94</a>]. This is because the patient's plasma can be separated from red blood cells (RBCs), cooled within the circuit, the precipitated cryoproteins removed using a filter, and the remaining plasma warmed and returned to the patient. In a series of five patients with CAD treated with CFA, two had an excellent response after a single treatment (including one who subsequently underwent coronary artery bypass grafting); the remaining three tolerated the procedure well but their improvement was attributed to other interventions [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> – There is less experience using IVIG in CAD, and the efficacy has not been well characterized. </p><p></p><p class="headingAnchor" id="H1150860656"><span class="h3">Transfusions</span><span class="headingEndMark"> — </span>Transfusions can and should be provided when indicated. Some individuals may have mild disease and may only require transfusions in the setting of severe hemolysis precipitated by infection or during the winter months [<a href="#rid9">9,40</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Unlike with warm autoimmune hemolytic anemia (AIHA), pretransfusion testing and crossmatching can be performed without interference by the autoantibody, provided the transfusion service is alerted to the presence of the cold agglutinin and cooling of the patient sample is avoided [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The blood (and any co-administered solutions) should be warmed appropriately prior to transfusion (typically, using a blood warmer to raise the temperature to body temperature) [<a href="#rid9">9,81</a>]. It is important not to heat the blood above 40°C because this will cause thermal hemolysis. (See  <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">"Hemolytic transfusion reactions", section on 'Non-immune hemolysis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient should be kept warm, especially in the extremity through which the transfusion is administered.</p><p></p><p class="headingAnchor" id="H1747999254"><span class="h2">Erythropoietin</span><span class="headingEndMark"> — </span>Patients with severe anemia and an inadequate bone marrow response (low reticulocyte count) may benefit from modest doses of erythropoietin (40,000 units subcutaneously once or twice a week), although evidence to support this approach in CAD is based on small retrospective studies [<a href="#rid95">95,96</a>]. </p><p class="headingAnchor" id="H19"><span class="h2">Therapies directed at the pathogenic process</span></p><p class="headingAnchor" id="H3154864019"><span class="h3">Indications for anti-B-cell therapy (primary CAD)</span></p><p class="bulletIndent1"><span class="glyph">●</span>In typical primary CAD, with or without a detectable low-grade bone marrow lymphoproliferative disorder, treatment is indicated for individuals who have symptomatic anemia, considerable fatigue, and/or cold-induced ischemic symptoms interfering with daily living  (<a class="graphic graphic_algorithm graphicRef138277" href="/z/d/graphic/138277.html" rel="external">algorithm 1</a>). Asymptomatic individuals can be followed without drug therapy. </p><p></p><p class="bulletIndent1">Treatment aims at targeting the pathogenic B-cell clone in the bone marrow to reduce the production of monoclonal cold agglutinin. Therapy generally involves <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in combination or as monotherapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most individuals who require treatment (due to significant hemolytic anemia or cold-induced symptoms), we generally use a rituximab-containing regimen such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a>. (See <a class="local">'Rituximab-containing regimens'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals for whom a rituximab-containing regimen is ineffective, we use <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>. (See <a class="local">'Bortezomib'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">Ibrutinib</a> can also be considered as a second-line B-cell targeting therapy, although the effect has only been documented in retrospective studies [<a href="#rid34">34,97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with cold agglutinin syndrome (CAS) secondary to an overt lymphoma that requires treatment by itself, such as an aggressive B-cell lymphoma, there is no documented therapy apart from appropriate treatment for the specific type of lymphoma. Choice of regimen is discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">"Treatment and prognosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CAS secondary to infection have a polyclonal cold agglutinin that will resolve spontaneously, typically over two to four weeks following resolution of the infection. Antibiotics or antiviral therapies should be used when indicated, as discussed in separate topic reviews. (See  <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8318.html" rel="external">"Infectious mononucleosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If an underlying autoimmune disorder is identified, treatment should be directed at the underlying disorder. </p><p></p><p class="headingAnchor" id="H3700958761"><span class="h3">Rituximab-containing regimens</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> may be used alone or in combination with other agents. We generally individualize decisions about adding a second agent, balancing the toxicity profile and other burdens with the severity of disease. </p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> produces high response rates and often complete responses lasting for many years. However, toxicities may be greater than with rituximab monotherapy, limiting use of this combination in frail individuals [<a href="#rid9">9,34</a>]. </p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> plus <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> is more toxic and should be reserved for third-line therapy in selected patients.</p><p class="headingAnchor" id="H3477094725"><span class="h4">Rituximab plus bendamustine</span><span class="headingEndMark"> — </span>We generally prefer <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> for individuals with chronic primary CAD, based on high, durable response rates demonstrated in observational studies [<a href="#rid3">3</a>]. (See <a class="local">'Evidence for efficacy'</a> below.)</p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> can be given at a dose of 375 mg/m<sup>2</sup> on day 1, with <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> given at a dose of 90 mg/m<sup>2</sup> on days 1 and 2 for four cycles at a 28-day interval. As noted below, we generally give four cycles of therapy. (See <a class="local">'Monitoring and duration of therapy'</a> below.)</p><p>It is useful to note that <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> is a highly effective combination for Waldenström macroglobulinemia (WM), which is one of the lymphoid malignancies most often associated with CAD. This combination was effective in treating CAD in two older patients with WM after multiple courses of other agents were ineffective [<a href="#rid98">98,99</a>]. (See  <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">"Treatment and prognosis of Waldenström macroglobulinemia", section on 'Bendamustine plus rituximab'</a>.)</p><p class="headingAnchor" id="H2937012928"><span class="h4">Rituximab single agent or rituximab plus interferon</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Single agent </strong><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> – Monotherapy with rituximab is a good option for individuals who cannot tolerate multi-agent regimens. </p><p></p><p class="bulletIndent1">Typical <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> doses when used as a single agent are based on those used to treat B-cell malignancies (eg, 375 mg/m<sup>2</sup> weekly for four weeks) [<a href="#rid100">100,101</a>]. Rituximab can be given at a dose of 375 mg/m<sup>2</sup> once weekly for four weeks, with or without interferon alfa at a dose of 5 million units subcutaneously three times per week, starting two weeks before retreatment with rituximab. </p><p></p><p class="bulletIndent1">In a series of 27 patients with CAD treated with this regimen, responses were seen in 54 percent [<a href="#rid100">100</a>]. The median duration of response was 11 months. There were no serious adverse effects.</p><p></p><p class="bulletIndent1">Lower doses of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (eg, 100 mg fixed dose weekly for four weeks) have also been used, but with more frequent failures in CAD than in warm AIHA [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a><strong> plus </strong><a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> – Rituximab can be given at a dose of 375 mg/m<sup>2</sup> on days 1, 29, 57, and 85, with oral fludarabine 40 mg/m<sup>2</sup> on days 1 through 5, 29 through 34, 57 through 61, and 85 through 89. </p><p></p><p class="bulletIndent1">In a prospective study involving 29 patients treated with this regimen (10 of whom were previously treated with single-agent <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> without a response), responses were seen in 76 percent, with complete responses in 21 percent [<a href="#rid103">103</a>]. The estimated median response duration was in excess of 66 months. Grade 4 hematologic toxicity (absolute neutrophil count &lt;500/microL) occurred in four patients (14 percent), and <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> was discontinued or dose-reduced in 13 (45 percent).</p><p></p><p class="headingAnchor" id="H256950539"><span class="h4">Monitoring and duration of therapy</span><span class="headingEndMark"> — </span>Therapy is monitored by following the hemoglobin level, markers of hemolysis (eg, bilirubin, haptoglobin, lactate dehydrogenase [LDH], reticulocyte count), and IgM level. The frequency of testing is individualized depending on the severity of hemolytic anemia.</p><p>Responses to rituximab-based combinations can be delayed by several months and can deepen with time. Therefore, we do not continue these therapies beyond four cycles; conversely, we do not stop therapy in patients who have not had a response after three or fewer cycles [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H2994819687"><span class="h4">Evidence for efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> appears to be reasonable in CAD, although slightly less than in warm AIHA [<a href="#rid104">104</a>]. Randomized trials have not been performed. Case series have reported response rates of more than 50 percent; almost all responses are partial. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for </strong><strong>rituximab</strong><strong>-containing regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2013 retrospective series of 89 patients with CAD treated with a variety of therapies, rituximab-based therapy gave response rates of 83 percent (single agent) and 79 percent (combination therapy) [<a href="#rid35">35</a>]. These rates were higher than many of the other immunosuppressive or cytotoxic agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 2006 series of 86 patients with CAD treated with a variety of therapies, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> was used in 52, with response rates on the order of 67 percent; complete response was more likely with combination therapy than with single-agent rituximab, and rituximab-based therapy was more effective than other immunosuppressive or cytotoxic agents [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Smaller series have reported similar response rates with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, alone or in combination with other therapies [<a href="#rid100">100,101,103-106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for </strong><strong>rituximab</strong><strong> plus </strong><strong>bendamustine</strong> – Observational data show good outcomes with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> and suggest that rituximab plus bendamustine may be less toxic and associated with a higher rate and longer duration of response than rituximab plus <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a prospective study involving 45 patients treated with this regimen, responses were seen in 32 individuals (71 percent), with complete responses in 18 (40 percent). Of those who had a response, only three (&lt;10 percent) relapsed after 32 months [<a href="#rid106">106</a>]. Grade 3 neutropenia was seen in 15 patients (33 percent), and infection developed in five (11 percent). The median time to response was 1.9 months (upper range, 12 months), with even longer time to optimal response in some patients. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A follow-up study that included additional individuals showed long-lasting responses [<a href="#rid34">34</a>]. Of 104 patients who received at least one course of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> or rituximab plus <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, rituximab plus bendamustine was associated with the following favorable outcomes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Higher overall response rate – 78 versus 62 percent</p><p class="bulletIndent3"><span class="glyph">-</span>Higher complete response rate – 53 versus 38 percent</p><p class="bulletIndent3"><span class="glyph">-</span>Higher response rate at five years – 77 versus 71 percent</p><p></p><p class="bulletIndent2">The median response duration with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> was &gt;88 months. There was a trend towards a higher rate of late-occurring malignancies in patients who received rituximab plus <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a> (31 percent, versus 9 percent with rituximab plus bendamustine; not statistically significant). </p><p></p><p class="headingAnchor" id="H3947474809"><span class="h3">Bortezomib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a> is a proteasome inhibitor used in lymphoid (B-cell) malignancies. We would use bortezomib (short course, as described in the study below) in individuals with an underlying B-cell or plasma cell disorder such as monoclonal gammopathy if rituximab-containing regimens are ineffective or contraindicated [<a href="#rid9">9</a>].</p><p>Evidence for the efficacy of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> comes from a 2018 study involving 21 individuals with CAD who had anemia and chronic hemolysis (hemoglobin &lt;10 g/dL) and for whom at least one prior therapy had been ineffective [<a href="#rid107">107</a>]. They were treated with bortezomib as a single cycle of 1.3 mg/m<sup>2</sup> given intravenously on days 1, 4, 8, and 11. Oral <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> was administered as prophylaxis for herpes zoster reactivation. Six of 19 evaluable patients (32 percent) had a response (defined as transfusion independence or a 2 g/dL increase in hemoglobin level); the response was complete in three and partial in three. In four of the six individuals, the response was lasting (median duration, 16 months). Therapy was well tolerated with only a single grade 3 to 4 adverse event that was considered treatment-related (upper respiratory tract infection). Case reports and our experience are consistent with these results [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H1437487639"><span class="h3">Daratumumab</span><span class="headingEndMark"> — </span>Two case reports have described promising results with <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> in individuals with severe CAD refractory to B-cell directed therapies [<a href="#rid110">110,111</a>]. Further data are needed before this approach is adopted.</p><p class="headingAnchor" id="H582882849"><span class="h3">Therapies unlikely to be effective (glucocorticoids and splenectomy)</span><span class="headingEndMark"> — </span>Glucocorticoids and splenectomy are not effective therapies in the majority of patients with CAD, in contrast to warm AIHA where these therapies are generally very effective [<a href="#rid3">3,9,12,35</a>]. </p><p>Glucocorticoids may downregulate phagocytosis, but they do not block antibody production. Exceptions may include individuals with IgG cold-reacting antibodies, antibodies with a higher thermal amplitude that cause some warm hemolysis, or mixed warm and cold AIHA. Splenectomy is likely to be ineffective because the liver, not the spleen, is the main site of RBC phagocytosis in CAD. As with glucocorticoids, splenectomy may be effective in rare individuals who have a high thermal amplitude antibody or a mixed warm and cold AIHA [<a href="#rid10">10,12</a>].</p><p>Other cytotoxic or immunosuppressive therapies that have been tried include <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> or <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">chlorambucil</a> (often in combination with glucocorticoids) or interferon alfa [<a href="#rid35">35,112-114</a>]. These might be appropriate in selected patients if <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and/or <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> have failed to reduce antibody production. Individuals treated with these therapies should be aware of the limited evidence for efficacy.</p><p class="headingAnchor" id="H1875735222"><span class="h2">Anti-complement therapies</span><span class="headingEndMark"> — </span>Therapies that target the classical complement pathway components responsible for extravascular hemolysis in CAD can be used to reduce transfusion requirements and improve anemia and fatigue [<a href="#rid65">65</a>]. </p><p>Complement-directed therapies do not eliminate the cells producing the cold agglutinins, and they would not be expected to improve cold-induced symptoms related to RBC agglutination, as agglutination is mediated by the IgM molecules and is complement independent [<a href="#rid9">9</a>]. Inherited deficiencies of proximal complement components cause systemic lupus erythematosus (SLE) and recurrent bacterial infections, suggesting that these proteins have important roles in normal immune function. However, appearance of antinuclear antibodies or occurrence of clinical SLE has not been reported in clinical studies of proximal complement inhibition [<a href="#rid65">65,115</a>]. (See  <a class="medical medical_review" href="/z/d/html/3962.html" rel="external">"Inherited disorders of the complement system", section on 'C1 deficiency'</a>.) </p><p>Furthermore, complement-directed therapies will have to be continued indefinitely, in contrast to B cell-directed therapies, which are temporary. Therefore, complement-directed therapies are generally reserved for individuals whose disease does not improve with immunosuppressive therapies such as <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, and/or <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, those who cannot take these therapies, or those who require a more rapidly acting or transient blockade of hemolysis. (See <a class="local">'Therapies directed at the pathogenic process'</a> above.)</p><p><a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">Eculizumab</a> and related monoclonal antibodies that target the more distal complement component C5 are not expected to lessen hemolysis, which is mostly extravascular and mediated by upstream components of the classical complement pathway, although reports have described reduction of hemolysis in selected individuals [<a href="#rid74">74,116-119</a>]. (See <a class="local">'Mechanism of hemolysis'</a> above.)</p><p class="headingAnchor" id="H822549282"><span class="h3">Sutimlimab (anti-C1)</span><span class="headingEndMark"> — </span>Complement component C1 is an attractive target because it has enzymatic activity and is upstream of a number of other classical pathway components  (<a class="graphic graphic_figure graphicRef56374" href="/z/d/graphic/56374.html" rel="external">figure 1</a>). C1 consists of three subunits (C1r, C1s, and C1q)  (<a class="graphic graphic_figure graphicRef63027" href="/z/d/graphic/63027.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3968.html" rel="external">"Complement pathways"</a>.)</p><p><a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">Sutimlimab</a> (previously called TNT009 or BIVV009) is a humanized monoclonal antibody targeting C1s that can reduce extravascular hemolysis mediated by C3b [<a href="#rid37">37,120-123</a>]. It was approved for CAD by the US Food and Drug Administration (FDA) in early 2022.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – The exact indications for <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> in CAD have not been determined. The FDA-approved indication is hemolysis in CAD. In early 2023, the indication was extended by removing transfusion history as a requirement [<a href="#rid124">124</a>]. Sutimlimab has also been approved in Japan and the European Union [<a href="#rid125">125</a>]. Based on available evidence, we suggest sutimlimab for the following individuals:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with symptomatic anemia who are awaiting the effects of definitive therapy with a rituximab-containing regimen or those in whom a rituximab-containing regimen is not appropriate or contraindicated. During the COVID-19 pandemic, this group will include individuals who are not fully vaccinated or who face a high risk of severe disease if infected and as a result wish to avoid <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, which is immunosuppressive. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with hemolytic anemia that is unresponsive to B cell-directed therapies. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who require a rapid response due to severe anemia or acute exacerbations of hemolysis that do not resolve spontaneously. In these cases, <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> may be used as a "bridge" to B cell-directed approaches because it has a much more rapid onset of response. Severe anemia can be controlled with sutimlimab while B cell-directed therapy is initiated and while waiting for cold agglutinin production to cease. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who are undergoing cardiac surgery. In these individuals, a prophylactic dose of <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> given preoperatively may prevent a CAD exacerbation associated with hypothermia [<a href="#rid1">1,3,65,89,90,126</a>]. (See  <a class="medical medical_review" href="/z/d/html/140569.html" rel="external">"Cardiac surgery with cardiopulmonary bypass in patients with cold agglutinin disease", section on 'Cold agglutinins versus cold agglutinin disease'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">Sutimlimab</a> is generally not appropriate as standalone therapy if bothersome, cold-induced circulatory symptoms are part of the indication for treatment [<a href="#rid1">1,65</a>]. Cold-induced symptoms are caused by RBC agglutination and are not complement-mediated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The dose is given intravenously, once weekly for two weeks and once every two weeks thereafter: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Weight 39 to 75 kg – 6500 mg </p><p class="bulletIndent2"><span class="glyph">•</span>Weight ≥75 kg – 7500 mg</p><p></p><p class="bulletIndent1">Patients should receive vaccinations against encapsulated bacteria (<em>Neisseria meningitidis, Haemophilus influenzae</em>, and <em>Streptococcus pneumoniae</em>) at least two weeks before starting <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a>; if therapy is started urgently, vaccines should be provided as soon as possible.</p><p></p><p class="bulletIndent1">The duration of therapy depends on whether cold agglutinins continue to be produced, since <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> only blocks hemolysis and does not treat the source of cold agglutinin production. As the indication for sutimlimab is restricted to primary CAD, therapy will probably have to be continued indefinitely if not used as a "bridge" to B-cell directed therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">Sutimlimab</a> can increase the risk of serious bacterial infections, especially from encapsulated organisms, as well as infusion reactions [<a href="#rid124">124</a>]. Based on its mechanism of action, sutimlimab might increase the risk of autoimmune diseases such as lupus, although this has not been observed in clinical studies. Hemolysis will usually recur after discontinuation of therapy, unless the underlying condition causing cold agglutinin production has been treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – A 2022 trial (CADENZA) that randomly assigned 42 patients with CAD and hemoglobin &lt;10 g/dL to <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> or placebo demonstrated increased mean hemoglobin and decreased fatigue stores [<a href="#rid91">91</a>]. The composite endpoint of increased hemoglobin and avoidance of transfusions and CAD medications was met in 73 percent in the sutimlimab arm and three percent in the placebo arm. Markers of hemolysis were significantly improved, with normalized bilirubin in all the patients in the sutimlimab arm This trial and other studies excluded patients with &gt;10 percent lymphoid infiltration in the bone marrow; therefore, the favorable effect of sutimlimab is not documented in this subgroup.</p><p></p><p class="bulletIndent1">Prior single arm studies also documented increases in hemoglobin in individuals treated with <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> [<a href="#rid65">65,115,127</a>]. A prospective study of longer duration of use (washout period and retreatment for a total of 52 months) demonstrated sustained responses, with stable hemoglobin and reduced hemolysis markers [<a href="#rid128">128</a>]. All of the studies of sutimlimab have shown that therapy was well tolerated. Instances of sustained remission following discontinuation have also been reported [<a href="#rid129">129</a>].</p><p></p><p>Inhibitors of C1q are also under investigation for reducing hemolysis in CAD [<a href="#rid130">130</a>].</p><p class="headingAnchor" id="H397105092"><span class="h3">Pegcetacoplan (anti-C3)</span><span class="headingEndMark"> — </span>Complement protein C3 is the point of convergence between all three complement-activating pathways and the initiation of the terminal (lytic) pathway  (<a class="graphic graphic_figure graphicRef56374" href="/z/d/graphic/56374.html" rel="external">figure 1</a>). C3 inhibition is expected to block the entire complement system, including the classical pathway and ensuing C3b opsonization, which are the main drivers of hemolysis in CAD, and the terminal pathway, which is of importance in some patients and some situations [<a href="#rid131">131</a>].</p><p><a class="drug drug_general" data-topicid="131650" href="/z/d/drug information/131650.html" rel="external">Pegcetacoplan</a> (previously termed APL-2) is a pegylated cyclic peptide inhibitor of C3 that is designed for subcutaneous administration. Preliminary outcomes from a study of pegcetacoplan therapy in AIHA, reported in abstract form, documented an efficacy in two individuals with CAD, who had an increase in hemoglobin levels by 3 g/dL and 5.7 g/dL, respectively, after 8 to 12 weeks of treatment [<a href="#rid131">131,132</a>]. Both individuals had an increase in hemoglobin to &gt;13 g/dL, and the drug was well tolerated. Participants were vaccinated as in the <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> trials. Possible concerns and limitations are expected to be similar to sutimlimab. Further trials will need to evaluate the risk of infection with encapsulated bacteria.</p><p class="headingAnchor" id="H66397180"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Median survival appears to be similar to or only slightly decreased compared with an age-matched population [<a href="#rid12">12,34,35</a>]. In the largest series, survival from the time of diagnosis (at a median age of 68 years) was 16 years, with an estimated five-year survival of 83 percent [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1583869837"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">"Society guideline links: Anemia in adults"</a>.)</p><p class="headingAnchor" id="H109983861"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83062.html" rel="external">"Patient education: Autoimmune hemolytic anemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Cold agglutinins are IgM antibodies against red blood cells (RBCs) that are active below normal body temperature. They can cause RBC agglutination and extravascular hemolysis with anemia. (See <a class="local">'Terminology and distinction among syndromes'</a> above and <a class="local">'Pathogenesis'</a> above and <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary cold agglutinin disease (CAD) has characteristic immunophenotypic and genetic changes  (<a class="graphic graphic_picture graphicRef119671" href="/z/d/graphic/119671.html" rel="external">picture 2</a>). Most individuals have an indolent lymphoproliferative disorder in the bone marrow. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary cold agglutinin syndrome (CAS) occurs with certain infections (<em>Mycoplasma pneumoniae</em>, infectious mononucleosis), autoimmune disorders, and lymphoid malignancies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The prevalence is 5 to 20 per million; CAD constitutes approximately one-fifth of autoimmune hemolytic anemias (AIHAs). Many individuals with primary CAD are &gt;60 years. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – CAD can cause cold-induced acrocyanosis, livedo reticularis, Raynaud phenomenon, and hemolytic anemia, which can be mild to severe. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – The complete blood count (CBC) and RBC indices may show anemia and spurious macrocytosis due to RBC agglutination  (<a class="graphic graphic_picture graphicRef50522" href="/z/d/graphic/50522.html" rel="external">picture 1</a>). Hemolysis is Coombs-positive for complement. A cold agglutinin titer is obtained on a blood sample that must be maintained at 37 to 40°C until the clot has formed and retracted and the serum has been removed. The table lists distinctions from paroxysmal cold hemoglobinuria (PCH) and cryoglobulinemia  (<a class="graphic graphic_table graphicRef103370" href="/z/d/graphic/103370.html" rel="external">table 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Terminology and distinction among syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – CAD is diagnosed by hemolysis, positive direct Coombs for complement C3d (usually negative for IgG), and cold agglutinin titer ≥64 at 4°C. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Antibody titer and thermal amplitude'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-diagnostic testing</strong> – Evaluation for an underlying disorder is appropriate, especially in older adults and individuals with comorbidities. Serum protein electrophoresis (SPEP) and immunoglobulin class quantification should be performed. If an underlying disorder is not identified, bone marrow with flow cytometry is obtained. (See <a class="local">'Testing for underlying disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis includes other causes of Raynaud phenomenon, other hemolytic anemias, transfusion reactions, and PCH. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>All patients</strong> – Our approach is summarized in the flowchart  (<a class="graphic graphic_algorithm graphicRef138277" href="/z/d/graphic/138277.html" rel="external">algorithm 1</a>). Cold exposures should be avoided until the underlying cause of CAD has resolved or been eliminated. This demands constant vigilance and is especially important in hospitalized patients and with cardiac surgery. (See <a class="local">'Cold avoidance'</a> above and  <a class="medical medical_review" href="/z/d/html/140569.html" rel="external">"Cardiac surgery with cardiopulmonary bypass in patients with cold agglutinin disease", section on 'Cold agglutinins versus cold agglutinin disease'</a>.)</p><p></p><p class="bulletIndent2">In extreme cases, it may be possible to reduce the cold agglutinin using plasmapheresis (if emergency cardiac surgery with cold cardioplegia is required). (See <a class="local">'Plasmapheresis or IVIG as a temporizing measure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe symptoms</strong> – For symptomatic individuals (anemia, fatigue, cold-induced symptoms), the need for intervention depends on severity. (See <a class="local">'Overview of the approach to treatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For severe anemia (hemoglobin &lt;7 to 8 g/dL or hemodynamic compromise), RBC transfusions should be provided. (See <a class="local">'Emergency and supportive therapies for anemia'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For anemia that requires transfusions or causes severe symptoms, we suggest <a class="drug drug_general" data-topicid="134951" href="/z/d/drug information/134951.html" rel="external">sutimlimab</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Sutimlimab can be used as a temporizing measure until cold agglutinins resolve or are eliminated (as a bridge while awaiting definitive therapy or prior to cardiovascular surgery), or chronically in individuals who cannot receive therapies to eliminate cold agglutinins (eg, if they wish to avoid <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> during the COVID-19 pandemic) or if these therapies are ineffective. Sutimlimab only treats hemolysis and fatigue; it is not expected to treat or prevent cold-induced circulatory symptoms. (See <a class="local">'Sutimlimab (anti-C1)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Primary CAD</strong> – Inclusion in prospective trials is encouraged. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with anemia and/or symptoms, we suggest <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> plus <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> rather than other regimens or no B-cell directed treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)<em>.</em> Single agent rituximab may be more appropriate in frail individuals. <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a> or <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> are also options. These therapies may take weeks to months to be effective, and faster-acting interventions to treat severe anemia may be needed temporarily. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Asymptomatic individuals can be followed without drug therapy<em>. </em>(See <a class="local">'Therapies directed at the pathogenic process'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary CAS</strong> – Therapy is directed at the underlying disorder. (See  <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4545.html" rel="external">"Overview of the treatment of chronic lymphocytic leukemia"</a> and  <a class="medical medical_review" href="/z/d/html/6654.html" rel="external">"Treatment and prognosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="headingAnchor" id="H531726001"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Wendell F Rosse, MD, who contributed to an earlier version of this topic review.</p><p>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Berentsen S. How I treat cold agglutinin disease. Blood 2021; 137:1295.</a></li><li><a class="nounderline abstract_t">Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev 2020; 41:100648.</a></li><li><a class="nounderline abstract_t">Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med 2021; 385:1407.</a></li><li><a class="nounderline abstract_t">Małecka A, Trøen G, Tierens A, et al. Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease. Br J Haematol 2018; 183:838.</a></li><li><a class="nounderline abstract_t">JENKINS WJ, MARSH WL, NOADES J, et al. The I antigen and antibody. Vox Sang 1960; 5:97.</a></li><li><a class="nounderline abstract_t">Marsh WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haematol 1961; 7:200.</a></li><li><a class="nounderline abstract_t">Feizi T. The blood group Ii system: a carbohydrate antigen system defined by naturally monoclonal or oligoclonal autoantibodies of man. Immunol Commun 1981; 10:127.</a></li><li><a class="nounderline abstract_t">Roelcke D, Kreft H, Hack H, Stevenson FK. Anti-j: human cold agglutinins recognizing linear (i) and branched (I) type 2 chains. Vox Sang 1994; 67:216.</a></li><li><a class="nounderline abstract_t">Berentsen S. How I manage patients with cold agglutinin disease. Br J Haematol 2018; 181:320.</a></li><li><a class="nounderline abstract_t">Silberstein LE, Berkman EM, Schreiber AD. Cold hemagglutinin disease associated with IgG cold-reactive antibody. Ann Intern Med 1987; 106:238.</a></li><li><a class="nounderline abstract_t">Pereira A, Mazzara R, Escoda L, et al. Anti-Sa cold agglutinin of IgA class requiring plasma-exchange therapy as early manifestation of multiple myeloma. Ann Hematol 1993; 66:315.</a></li><li><a class="nounderline abstract_t">Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006; 91:460.</a></li><li><a class="nounderline abstract_t">Römer W, Rother U, Roelcke D. Failure of IgA cold agglutinin to activate C. Immunobiology 1980; 157:41.</a></li><li><a class="nounderline abstract_t">Sefland Ø, Randen U, Berentsen S. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? Case Rep Hematol 2019; 2019:1610632.</a></li><li><a class="nounderline abstract_t">Rosse WF. The detection of small amounts of antibody on the red cell in autoimmune hemolytic anemia. Ser Haematol 1974; 7:358.</a></li><li><a class="nounderline abstract_t">Rosse WF, Adams JP. The variability of hemolysis in the cold agglutinin syndrome. Blood 1980; 56:409.</a></li><li><a class="nounderline abstract_t">Berentsen S, Randen U, Tjønnfjord GE. Cold agglutinin-mediated autoimmune hemolytic anemia. Hematol Oncol Clin North Am 2015; 29:455.</a></li><li><a class="nounderline abstract_t">Pascual V, Victor K, Spellerberg M, et al. VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities. J Immunol 1992; 149:2337.</a></li><li><a class="nounderline abstract_t">Smith G, Spellerberg M, Boulton F, et al. The immunoglobulin VH gene, VH4-21, specifically encodes autoanti-red cell antibodies against the I or i antigens. Vox Sang 1995; 68:231.</a></li><li><a class="nounderline abstract_t">Silberstein LE, Jefferies LC, Goldman J, et al. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 1991; 78:2372.</a></li><li><a class="nounderline abstract_t">Potter KN. Molecular characterization of cold agglutinins. Transfus Sci 2000; 22:113.</a></li><li><a class="nounderline abstract_t">Pascual V, Victor K, Lelsz D, et al. Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. J Immunol 1991; 146:4385.</a></li><li><a class="nounderline abstract_t">Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica 2014; 99:497.</a></li><li><a class="nounderline abstract_t">Thompson KM, Sutherland J, Barden G, et al. Human monoclonal antibodies against blood group antigens preferentially express a VH4-21 variable region gene-associated epitope. Scand J Immunol 1991; 34:509.</a></li><li><a class="nounderline abstract_t">Stevenson FK, Longhurst C, Chapman CJ, et al. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun 1993; 6:809.</a></li><li><a class="nounderline abstract_t">Bieber MM, Bhat NM, Teng NN. Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene. Clin Infect Dis 1995; 21 Suppl 2:S186.</a></li><li><a class="nounderline abstract_t">Potter KN, Hobby P, Klijn S, et al. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol 2002; 169:3777.</a></li><li><a class="nounderline abstract_t">Cauerhff A, Braden BC, Carvalho JG, et al. Three-dimensional structure of the Fab from a human IgM cold agglutinin. J Immunol 2000; 165:6422.</a></li><li><a class="nounderline abstract_t">Rosenthal F, Corten M. Uber das phänomenon der autohämagglutination und über die eigenschaften der kältehämagglutinine. Folia Haematol 1937; 58:64.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li class="breakAll">Naresh KN, Rossi D, Chen X, et al. Cold agglutinin disease. In: WHO Classification of Haematolymphoid Tumours, 5th ed, International Agency for Research on Cancer, Lyon 2022. p.349.</li><li><a class="nounderline abstract_t">Małecka A, Delabie J, Østlie I, et al. Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18. Blood Adv 2020; 4:993.</a></li><li><a class="nounderline abstract_t">Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood 2020; 136:480.</a></li><li><a class="nounderline abstract_t">Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood 2013; 122:1114.</a></li><li><a class="nounderline abstract_t">Baines AC, Brodsky RA. Complementopathies. Blood Rev 2017; 31:213.</a></li><li><a class="nounderline abstract_t">Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014; 123:4015.</a></li><li><a class="nounderline abstract_t">Zilow G, Kirschfink M, Roelcke D. Red cell destruction in cold agglutinin disease. Infusionsther Transfusionsmed 1994; 21:410.</a></li><li><a class="nounderline abstract_t">Mickley H, Sørensen PG. Immune haemolytic anaemia associated with ampicillin dependent warm antibodies and high titre cold agglutinins in a patient with Mycoplasma pneumonia. Scand J Haematol 1984; 32:323.</a></li><li><a class="nounderline abstract_t">Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014; 124:2930.</a></li><li><a class="nounderline abstract_t">Logue GL, Rosse WF, Gockerman JP. Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome. J Clin Invest 1973; 52:493.</a></li><li><a class="nounderline abstract_t">Kirschfink M, Knoblauch K, Roelcke D. Activation of complement by cold agglutinins. Infusionsther Transfusionsmed 1994; 21:405.</a></li><li><a class="nounderline abstract_t">Bylsma LC, Gulbech Ording A, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv 2019; 3:2980.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed) 1981; 282:2023.</a></li><li><a class="nounderline abstract_t">Lind K, Benzon MW, Jensen JS, Clyde WA Jr. A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995. Eur J Epidemiol 1997; 13:581.</a></li><li><a class="nounderline abstract_t">García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575.</a></li><li><a class="nounderline abstract_t">Arthold C, Skrabs C, Mitterbauer-Hohendanner G, et al. Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings. Wien Klin Wochenschr 2014; 126:376.</a></li><li><a class="nounderline abstract_t">Wortman J, Rosse W, Logue G. Cold agglutinin autoimmune hemolytic anemia in nonhematologic malignancies. Am J Hematol 1979; 6:275.</a></li><li><a class="nounderline abstract_t">Feizi T. Monotypic cold agglutinins in infection by mycoplasma pneumoniae. Nature 1967; 215:540.</a></li><li><a class="nounderline abstract_t">Nixon CP, Sweeney JD. Facilitation of the clinical diagnosis of Mycoplasma pneumoniae by the blood bank. Transfusion 2017; 57:2564.</a></li><li><a class="nounderline abstract_t">Stein B, DeCredico N, Hillman L. Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection. JAMA 2018; 319:1377.</a></li><li><a class="nounderline abstract_t">Horwitz CA, Moulds J, Henle W, et al. Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes. Blood 1977; 50:195.</a></li><li><a class="nounderline abstract_t">Terada K, Tanaka H, Mori R, et al. Hemolytic anemia associated with cold agglutinin during chickenpox and a review of the literature. J Pediatr Hematol Oncol 1998; 20:149.</a></li><li><a class="nounderline abstract_t">König AL, Schabel A, Sugg U, et al. Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection. Transfusion 2001; 41:488.</a></li><li><a class="nounderline abstract_t">Ciaffoni S, Luzzati R, Roata C, et al. Presence and significance of cold agglutinins in patients with HIV infection. Haematologica 1992; 77:233.</a></li><li><a class="nounderline abstract_t">Zagorski E, Pawar T, Rahimian S, Forman D. Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19). Br J Haematol 2020; 190:e183.</a></li><li><a class="nounderline abstract_t">Oshima M, Maeda H, Morimoto K, et al. Low-titer cold agglutinin disease with systemic sclerosis. Intern Med 2004; 43:139.</a></li><li><a class="nounderline abstract_t">Honne K, Nagashima T, Iwamoto M, et al. Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis. Case Rep Rheumatol 2015; 2015:823563.</a></li><li><a class="nounderline abstract_t">Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 2012; 26:107.</a></li><li><a class="nounderline abstract_t">Hill QA, Hill A, Berentsen S. Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv 2019; 3:1897.</a></li><li><a class="nounderline abstract_t">Hansen DL, Berentsen S, Fattizzo B, et al. Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy. Am J Hematol 2021; 96:E262.</a></li><li><a class="nounderline abstract_t">Röth A, Fryzek J, Jiang X, et al. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2022; 62:51.</a></li><li><a class="nounderline abstract_t">Findlater RR, Schnell-Hoehn KN. When blood runs cold: cold agglutinins and cardiac surgery. Can J Cardiovasc Nurs 2011; 21:30.</a></li><li><a class="nounderline abstract_t">Jain MD, Cabrerizo-Sanchez R, Karkouti K, et al. Seek and you shall find--but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery. Transfus Med Rev 2013; 27:65.</a></li><li><a class="nounderline abstract_t">Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med 2021; 384:1323.</a></li><li><a class="nounderline abstract_t">Poldre P, Pruzanski W, Chiu HM, Dotten DA. Fulminant gangrene in transient cold agglutinemia associated with Escherichia coli infection. Can Med Assoc J 1985; 132:261.</a></li><li><a class="nounderline abstract_t">Oh SH, Kim DS, Ryu DJ, Lee KH. Extensive cutaneous necrosis associated with low titres of cold agglutinins. Clin Exp Dermatol 2009; 34:e229.</a></li><li><a class="nounderline abstract_t">de Witte MA, Determann RM, Zeerleder SS. A man with "black fingers". Cold agglutinin disease (CAD). Neth J Med 2014; 72:35, 39.</a></li><li><a class="nounderline abstract_t">Iwasaki H. Acronecrosis with cold agglutinin disease mimics diabetic gangrene. Intern Med 2013; 52:837.</a></li><li><a class="nounderline abstract_t">Lyckholm LJ, Edmond MB. Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome. N Engl J Med 1996; 334:437.</a></li><li><a class="nounderline abstract_t">Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol 2001; 54:239.</a></li><li><a class="nounderline abstract_t">Röth A, Broome CM, Barcellini W, et al. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study. Eur J Haematol 2023; 110:280.</a></li><li><a class="nounderline abstract_t">Röth A, Barcellini W, Tvedt THA, et al. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study. Ann Hematol 2022; 101:2169.</a></li><li><a class="nounderline abstract_t">Röth A, Bommer M, Hüttmann A, et al. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial. Blood Adv 2018; 2:2543.</a></li><li><a class="nounderline abstract_t">Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost 2020; 4:628.</a></li><li><a class="nounderline abstract_t">Bessman JD, Banks D. Spurious macrocytosis, a common clue to erythrocyte cold agglutinins. Am J Clin Pathol 1980; 74:797.</a></li><li><a class="nounderline abstract_t">Hinchliffe RF, Bellamy GJ, Lilleyman JS. Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration. Clin Lab Haematol 1992; 14:268.</a></li><li><a class="nounderline abstract_t">Zandecki M, Genevieve F, Gerard J, Godon A. Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. Int J Lab Hematol 2007; 29:21.</a></li><li><a class="nounderline abstract_t">Bendix BJ, Tauscher CD, Bryant SC, et al. Defining a reference range for cold agglutinin titers. Transfusion 2014; 54:1294.</a></li><li><a class="nounderline abstract_t">Hill QA, Stamps R, Massey E, et al. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol 2017; 177:208.</a></li><li><a class="nounderline abstract_t">Hill QA, Stamps R, Massey E, et al. The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 2017; 176:395.</a></li><li><a class="nounderline abstract_t">Berentsen S, D'Sa S, Randen U, et al. Cold agglutinin disease: Improved understanding of pathogenesis helps define targets for therapy. Hemato 2022; 3:574.</a></li><li><a class="nounderline abstract_t">Gertz MA. Management of cold haemolytic syndrome. Br J Haematol 2007; 138:422.</a></li><li><a class="nounderline abstract_t">Talisman R, Lin JT, Soroff HS, Galanakis D. Gangrene of the back, buttocks, fingers, and toes caused by transient cold agglutinemia induced by a cooling blanket in a patient with sepsis. Surgery 1998; 123:592.</a></li><li><a class="nounderline abstract_t">Bedrosian CL, Simel DL. Cold hemagglutinin disease in the operating room. South Med J 1987; 80:466.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Ghosh PK, Gupta D. Cardiac surgery and cold-reactive proteins. Ann Thorac Surg 1995; 60:1143.</a></li><li><a class="nounderline abstract_t">Beebe DS, Bergen L, Palahniuk RJ. Anesthetic management of a patient with severe cold agglutinin hemolytic anemia utilizing forced air warming. Anesth Analg 1993; 76:1144.</a></li><li><a class="nounderline abstract_t">Barbara DW, Mauermann WJ, Neal JR, et al. Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass. J Thorac Cardiovasc Surg 2013; 146:668.</a></li><li><a class="nounderline abstract_t">Tjønnfjord E, Vengen ØA, Berentsen S, Tjønnfjord GE. Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Tvedt THA, Steien E, Øvrebø B, et al. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol 2022; 97:E51.</a></li><li><a class="nounderline abstract_t">Röth A, Berentsen S, Barcellini W, et al. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial. Blood 2022; 140:980.</a></li><li><a class="nounderline abstract_t">Zoppi M, Oppliger R, Althaus U, Nydegger U. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusionsmed 1993; 20:19.</a></li><li><a class="nounderline abstract_t">Geurs F, Ritter K, Mast A, Van Maele V. Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase. Acta Haematol 1992; 88:142.</a></li><li><a class="nounderline abstract_t">Siami FS, Siami GA. A last resort modality using cryofiltration apheresis for the treatment of cold hemagglutinin disease in a Veterans Administration hospital. Ther Apher Dial 2004; 8:398.</a></li><li><a class="nounderline abstract_t">Salama A, Hartnack D, Lindemann HW, et al. The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia. Transfus Med Hemother 2014; 41:462.</a></li><li><a class="nounderline abstract_t">Fattizzo B, Michel M, Zaninoni A, et al. Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. Haematologica 2021; 106:622.</a></li><li><a class="nounderline abstract_t">Jalink M, Berentsen S, Castillo JJ, et al. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood 2021; 138:2002.</a></li><li><a class="nounderline abstract_t">Gueli A, Gottardi D, Hu H, et al. Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report. Blood Transfus 2013; 11:311.</a></li><li><a class="nounderline abstract_t">Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010; 115:915.</a></li><li><a class="nounderline abstract_t">Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103:2925.</a></li><li><a class="nounderline abstract_t">Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006; 47:253.</a></li><li><a class="nounderline abstract_t">Fattizzo B, Zaninoni A, Pettine L, et al. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. Blood 2019; 133:996.</a></li><li><a class="nounderline abstract_t">Berentsen S, Randen U, Vågan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010; 116:3180.</a></li><li><a class="nounderline abstract_t">Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol 2013; 91:546.</a></li><li><a class="nounderline abstract_t">Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood 2012; 119:3691.</a></li><li><a class="nounderline abstract_t">Berentsen S, Randen U, Oksman M, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 2017; 130:537.</a></li><li><a class="nounderline abstract_t">Rossi G, Gramegna D, Paoloni F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018; 132:547.</a></li><li><a class="nounderline abstract_t">Izumi M, Tsunemine H, Suzuki Y, et al. Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib. Int J Hematol 2015; 102:238.</a></li><li><a class="nounderline abstract_t">Adam Z, Pejchalová A, Chlupová G, et al. [Cold agglutinin disease -  no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature]. Vnitr Lek 2013; 59:828.</a></li><li><a class="nounderline abstract_t">Tomkins O, Berentsen S, Arulogun S, et al. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol 2020; 95:E293.</a></li><li><a class="nounderline abstract_t">Zaninoni A, Giannotta JA, Gallì A, et al. The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol 2021; 12:649441.</a></li><li><a class="nounderline abstract_t">Budmiger H, Rhyner K, Siegenthaler-Zuber G, Bollinger A. [Idiopathic cold agglutinin disease. Clinical aspects, therapy and course in 6 patients]. Schweiz Med Wochenschr 1988; 118:52.</a></li><li><a class="nounderline abstract_t">Rordorf R, Barth A, Nydegger U, Tobler A. [Treatment of severe idiopathic cold-agglutinin diseases using interferon-alpha 2b]. Schweiz Med Wochenschr 1994; 124:56.</a></li><li><a class="nounderline abstract_t">Fest T, de Wazières B, Lamy B, et al. Successful response to alpha-interferon 2b in a refractory IgM autoagglutinin-mediated hemolytic anemia. Ann Hematol 1994; 69:147.</a></li><li><a class="nounderline abstract_t">Jäger U, D'Sa S, Schörgenhofer C, et al. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial. Blood 2019; 133:893.</a></li><li><a class="nounderline abstract_t">Röth A, Hüttmann A, Rother RP, et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009; 113:3885.</a></li><li><a class="nounderline abstract_t">Gupta N, Wang ES. Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Ann Hematol 2014; 93:343.</a></li><li><a class="nounderline abstract_t">Makishima K, Obara N, Ishitsuka K, et al. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol 2019; 98:1031.</a></li><li><a class="nounderline abstract_t">Shapiro R, Chin-Yee I, Lam S. Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Rep 2015; 3:942.</a></li><li><a class="nounderline abstract_t">Derhaschnig U, Gilbert J, Jäger U, et al. Combined integrated protocol/basket trial design for a first-in-human trial. Orphanet J Rare Dis 2016; 11:134.</a></li><li><a class="nounderline abstract_t">Berentsen S. Cold agglutinin disease. Hematology Am Soc Hematol Educ Program 2016; 2016:226.</a></li><li><a class="nounderline abstract_t">Wahrmann M, Mühlbacher J, Marinova L, et al. Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study. Am J Transplant 2017; 17:2300.</a></li><li><a class="nounderline abstract_t">Mühlbacher J, Jilma B, Wahrmann M, et al. Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial. Transplantation 2017; 101:2410.</a></li><li class="breakAll">ENJAYMO (sutimlimab-jome) injection, for intravenous use. US Food and Drug Administration (FDA) approved product information. Revised Jan, 2023. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761164s003lbl.pdf (Accessed on January 27, 2023).</li><li class="breakAll">Sanofi. Press Release: European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease. Sanofi, Paris 2022. Available at: https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-17-17-50-00-2558583 (Accessed on March 07, 2023).</li><li><a class="nounderline abstract_t">Berentsen S. Cold agglutinins: fending off the attack. Blood 2019; 133:885.</a></li><li><a class="nounderline abstract_t">Gelbenegger G, Schoergenhofer C, Derhaschnig U, et al. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program. Blood Adv 2020; 4:997.</a></li><li><a class="nounderline abstract_t">Gelbenegger G, Jaeger U, Fillitz M, et al. Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial. Br J Haematol 2022; 198:e59.</a></li><li><a class="nounderline abstract_t">Gelbenegger G, Jäger U, Fillitz M, et al. Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease. Blood Adv 2023; 7:1987.</a></li><li><a class="nounderline abstract_t">Gertz MA, Qiu H, Kendall L, et al. ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease. Blood 2016; 128:1265.</a></li><li><a class="nounderline abstract_t">Berentsen S, Hill A, Hill QA, et al. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 2019; 10:2040620719873321.</a></li><li><a class="nounderline abstract_t">Grossi F, Shum MK, Gertz MA, et al. Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA). Blood 2018; 132:3623.</a></li></ol></div><div id="topicVersionRevision">Topic 7084 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512410" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : How I treat cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31839434" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614331" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Autoimmune Hemolytic Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29265349" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14407077" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The I antigen and antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13767181" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anti-i: a cold antibody defining the Ii relationship in human red cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6169630" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The blood group Ii system: a carbohydrate antigen system defined by naturally monoclonal or oligoclonal autoantibodies of man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7801615" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Anti-j: human cold agglutinins recognizing linear (i) and branched (I) type 2 chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29363757" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : How I manage patients with cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3800184" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cold hemagglutinin disease associated with IgG cold-reactive antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8318562" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anti-Sa cold agglutinin of IgA class requiring plasma-exchange therapy as early manifestation of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16585012" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7203511" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Failure of IgA cold agglutinin to activate C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30949369" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432071" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The detection of small amounts of antibody on the red cell in autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7407408" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The variability of hemolysis in the cold agglutinin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26043385" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cold agglutinin-mediated autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1382098" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660642" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The immunoglobulin VH gene, VH4-21, specifically encodes autoanti-red cell antibodies against the I or i antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1657249" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10771399" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular characterization of cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1710250" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24143001" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1718028" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Human monoclonal antibodies against blood group antigens preferentially express a VH4-21 variable region gene-associated epitope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8155258" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8845451" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Anti-endotoxin human monoclonal antibody A6H4C5 (HA-1A) utilizes the VH4.21 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12244172" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11086081" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Three-dimensional structure of the Fab from a human IgM cold agglutinin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Uber das phänomenon der autohämagglutination undüber die eigenschaften der kältehämagglutinine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32168377" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374875" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cold agglutinin disease revisited: a multinational, observational study of 232 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757733" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28215731" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Complementopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24695853" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873920" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Red cell destruction in cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6701467" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Immune haemolytic anaemia associated with ampicillin dependent warm antibodies and high titre cold agglutinins in a patient with Mycoplasma pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25232059" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4734261" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7873919" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Activation of complement by cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31648316" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6788179" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9258572" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A seroepidemiological study of Mycoplasma pneumoniae infections in Denmark over the 50-year period 1946-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11736938" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24842748" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/484548" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Cold agglutinin autoimmune hemolytic anemia in nonhematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4964492" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Monotypic cold agglutinins in infection by mycoplasma pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105832" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Facilitation of the clinical diagnosis of Mycoplasma pneumoniae by the blood bank.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29614161" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/194643" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hemolytic anemia associated with cold agglutinin during chickenpox and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316899" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1427429" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Presence and significance of cold agglutinins in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32460350" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005258" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Low-titer cold agglutinin disease with systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346552" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Glucocorticoid-Responsive Cold Agglutinin Disease in a Patient with Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330255" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31235526" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864697" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Seasonal variation in the incidence of cold agglutinin disease in Norway, Denmark, and Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34813663" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Complement-mediated hemolysis persists year round in patients with cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21630629" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : When blood runs cold: cold agglutinins and cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375735" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Seek and you shall find--but then what do you do? Cold agglutinins in cardiopulmonary bypass and a single-center experience with cold agglutinin screening before cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33826820" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sutimlimab in Cold Agglutinin Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881156" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fulminant gangrene in transient cold agglutinemia associated with Escherichia coli infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508583" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Extensive cutaneous necrosis associated with low titres of cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24457440" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A man with "black fingers". Cold agglutinin disease (CAD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545690" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acronecrosis with cold agglutinin disease mimics diabetic gangrene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8552146" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Images in clinical medicine. Seasonal hemolysis due to cold-agglutinin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11439172" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Acute phase haemolysis in chronic cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36403132" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35999387" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291112" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32548562" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446489" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Spurious macrocytosis, a common clue to erythrocyte cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451410" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224005" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Spurious counts and spurious results on haematology analysers: a review. Part II: white blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24898454" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Defining a reference range for cold agglutinin titers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369704" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28005293" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The diagnosis and management of primary autoimmune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cold agglutinin disease: Improved understanding of pathogenesis helps define targets for therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17561970" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Management of cold haemolytic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591016" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Gangrene of the back, buttocks, fingers, and toes caused by transient cold agglutinemia induced by a cooling blanket in a patient with sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3105086" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cold hemagglutinin disease in the operating room.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7574976" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cardiac surgery and cold-reactive proteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8484521" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Anesthetic management of a patient with severe cold agglutinin hemolytic anemia utilizing forced air warming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590925" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28487302" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34778998" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35687757" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504237" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1466197" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663535" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A last resort modality using cryofiltration apheresis for the treatment of cold hemagglutinin disease in a Veterans Administration hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670934" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32354865" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34293088" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23399352" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110437" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070665" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16321854" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30670440" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Low-dose rituximab in autoimmune hemolytic anemia: 10 years after.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634373" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033754" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267606" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533306" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29898955" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25794560" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24073955" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652632" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33732266" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344409" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : [Idiopathic cold agglutinin disease. Clinical aspects, therapy and course in 6 patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8296193" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : [Treatment of severe idiopathic cold-agglutinin diseases using interferon-alpha 2b].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8086510" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Successful response to alpha-interferon 2b in a refractory IgM autoagglutinin-mediated hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30559259" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19372265" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23722501" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Long-term response of refractory primary cold agglutinin disease to eculizumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30324459" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26576277" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27716293" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Combined integrated protocol/basket trial design for a first-in-human trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27913484" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28251805" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926521" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926521" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28926521" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30819775" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Cold agglutinins: fending off the attack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32176765" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35655238" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36322823" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : ANX005, an Inhibitory Antibody Against C1q, Blocks Complement Activation Triggered By Cold Agglutinins in Human Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31523413" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Novel insights into the treatment of complement-mediated hemolytic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA)</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
